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Summary 
Zopiclone is one of the most commonly prescribed sleep medications in the world. 
Driving in the morning, after regular nighttime zopiclone consumption, is, by many, 
considered to be safe traffic wise, due to the fast zopiclone elimination. Still, it is well 
known that the effects of zopiclone are comparable to that of benzodiazepines’, and 
certain negative effects due to zopiclone intake, with respect to traffic safety, are 
therefore to be expected. This thesis aimed to investigate if zopiclone was suitable for 
implementing legal limits, by the use of blood zopiclone concentrations, in a manner 
similar to what is being conducted for ethanol in most countries. With the previous being 
plausible, an increased traffic accident risk was expected to be found related to the use of 
zopiclone, in addition to a positive concentration-effect relationship between blood 
zopiclone concentrations and traffic-related impairment, comparable to that of what has 
been found for ethanol.  
We performed a coupling between the Norwegian Accident Registry (NRAR) and the 
Norwegian Prescription Database (NorPD), and found an increased traffic accident risk 
related to zopiclone exposure. There may, however, have been confounding factors 
present leading to a stronger relationship than what is actually true. Still, a significant 
traffic accident risk was found related to zopiclone exposure, in a case-crossover 
calculation, indicating a true drug effect. 
An observational study design was used to investigate the relationship between high 
blood zopiclone concentrations and impairment, in a population of apprehended 
suspected drugged drivers, as assessed by the Norwegian by-the-road clinical test for 
impairment (CTI). A high share of impairment was found, increasing the higher the blood 
zopiclone concentrations. Similar results were found for ethanol.  
Finally, a randomized controlled trial (RCT) was performed on 16 healthy volunteers. 
They were each given two different doses of zopiclone (5 and 10 mg), ethanol (50 g) and 
placebo, in a crossover design. The study found a positive concentration-effect 
relationship for zopiclone, as well as for ethanol. In addition, acute tolerance was found 
for zopiclone, as well as for ethanol. The relationship between blood zopiclone 
concentrations and blood alcohol concentrations (BACs) is found to be positive; 
however, there was some variation in response to the different impairment tests. 
In total, the presented studies indicate that blood zopiclone concentrations may be as 
suited for legal limits as BACs. 
4 
Funding 
The work related to Paper I and Paper II was funded by internal resources from The 
Norwegian Institute of Public Health.  
The work related to Paper III and Paper IV was funded by internal sources from The 
Norwegian Institute of Public Health, in addition to grants from The Ministry of Justice 
and The Ministry of Transport and Communications. 
5 
Acknowledgements 
The work presented has been carried out while I was appointed as a Senior Medical 
Officer at the Division of Forensic Medicine and Drug Abuse Research, at the Norwegian 
Institute of Public Health, between 2007 and 2012. During this time-period, I had a two-
year leave of absence, between 2009 and 2011, living with my family in South Korea and 
concurrently working on Papers III and IV. 
First of all, I am truly grateful to my Supervisor, Professor Jørg Mørland. Choosing you 
was a well-founded action, which I have never regretted. You are such an inspiring and 
knowledgeable person, always friendly and attentive. Your scientific awareness and 
broad overview within the field of pharmacology and forensic toxicology exceed most; 
always demonstrating enthusiastic glow for unsolved issues. Thank you for everything 
that you have taught me. I am also especially thankful to my co-supervisors: Professor 
Jørgen G. Bramness and Professor Svetlana Skurtveit. Jørgen, you have a contagious 
dedication to everything related to research, and I have thoroughly enjoyed working with 
you. Svetlana, I have particularly and highly appreciated your practical advice and wise 
comments. All in all, the three of you have complemented one another, each having 
taught me great amounts, and in summation, making this project a genuinely positive 
experience. I hope to continue the collaboration with each one of you in the future. 
Throughout the work on the four included papers, I have had the pleasure of cooperating 
with many knowledgeable and skilful co-authors. For Paper I, I was lucky enough to join 
a team of very experienced researchers: Professor Anders Engeland (the Norwegian 
Institute of Public Health, Bergen) and Professor Ineke Neutel (University of Ottawa, 
Canada), in addition to my three supervisors. I am indeed grateful for having had the 
opportunity to learn from all of you.  
Paper II was more of a local project, where I had the great pleasure of cooperating with 
Muhammad Al-Sammurraie, in addition to two of my supervisors. The results were 
retrieved from the routine analyses at the division, and I am truly thankful for all of the 
effort and the accuracy provided by the analytic staff.  
The trial leading to Papers III and IV was an immense project with numerous amounts of 
people being involved. Knut Hjelmeland, we shared a leadership role during this project. 
It has been a true pleasure to collaborate so closely with you. You are knowledgeable and 
orderly, always demonstrating a positive attitude. In particular, thank you for your 
friendship and motivating e-mails during my stay in South Korea. Jean-Paul Bernard, you 
were an essential part of the project group, being highly skilful and constructive; it has 
been a great pleasure working with you. In addition, many thanks go to all analytical 
colleagues for their hard work on this project. Nearly 500 blood samples were analyzed, 
requiring a lot of time and energy. In particular, great thanks go to the workers in Dr. 
Lena Kristofferson’s group, and to the workers in Professor Asbjørg S. Christophersen’s 
group. A warm thank you goes to colleagues at Oslo University Hospital, Rikshospitalet, 
for great enthusiasm and highly professional management during the clinical trial. 
6 
Throughout my period as a PhD candidate I have had different leaders, who have all been 
very supporting. I would like to express special thanks to Dr Håkon Aune, Dr Liliana 
Bachs and Dr Vigdis Vindenes, all for their encouraging leadership. 
Also many thanks go to all colleagues for their friendship, motivation and support. 
Working at “REFS” is an honestly positive experience, because of the unique fusion of 
friendly colleagues and a true excitement for pharmacology and forensic toxicology. It is 
always enjoyable and motivating working with you all. Thanks for enjoyable working 
time and precious friendships. 
I also have friendships outside this mentioned group of colleagues, who have played 
important roles in making me complete my PhD. I am indeed grateful to Ingeborg L. 
Vestad for fun times and hard work during our common PhD-weekends. Also, great 
thanks go to my close friends Siri R. Kristjansson and Marte C. R. Mellingsæter for warm 
friendships and for sharing our PhD-ups and downs. I would further like to express a 
warm appreciation to Na Won Lee for giving me meaningful PhD-breaks during my stay 
in South Korea. 
My greatest appreciation goes to my family: Thanks to my parents for always 
demonstrating a positive attitude and for being supportive in everything I have 
conducted. Finally, a large appreciation to my beloved ones: My husband Tor Endre, and 
our children Gerhard, Aurora and Emily. You are the most caring and supporting family I 
could ever wish for. Tor Endre, I could not do without our daily long conversations, most 
of them (thankfully) not concerning this PhD. Your deep love and true encouragement is 
essential for me in whatever I do.  
7 
  
List of papers 
Paper I 
Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J: Road 
Traffic Accident Risk Related to Prescription of the Hypnotics: Zopiclone, 
Zolpidem, Flunitrazepam and Nitrazepam. Sleep Med 2008; 9 (8) 818-822. 
Paper II 
Gustavsen I, Al-Sammurraie M, Mørland J, Bramness JG: Impairment Related to 
Blood Drug Concentrations of Zopiclone and Zolpidem Compared with Alcohol 
in Apprehended Drivers. Accid Anal Prev 2009; 41 (3) 462-466. 
Paper III 
Gustavsen I, Hjelmeland K, Bernard JP, Mørland J: Psychomotor Performance 
after Intake of Zopiclone compared with Intake of Ethanol– A randomized 
Controlled Double-Blinded Trial. J Clin psychopharmacol 2011; 31(4): 481-488. 
Paper IV 
Gustavsen I, Hjelmeland K, Bernard JP, Mørland J: Individual Psychomotor 
Impairment in Relation to Zopiclone and Ethanol Concentrations in Blood– A 
Randomized Controlled Double-Blinded Trial. Addiction 2012; 107(5):925-932.
8 
Abbreviations 
ATC  Anatomical Therapeutic Chemical 
BAC  Blood Alcohol Concentration 
BZ  Benzodiazepine 
CFF  Critical Flicker Fusion 
CI  Confidence Interval 
CNS  Central Nervous System 
CPT  Connors Continuous Performance Test  
CRT  Choice Reaction Time 
CTT  Critical Tracking Test 
CTI  Clinical Test for Impairment 
DEC  Drug Evaluation and Classification 
DRUID Driving Under the Influence of Drugs 
DSST  Digit Symbol Substitution Test 
DUI  Driving Under the Influence 
DUID  Driving Under the Influence of Drugs 
EMIT  Enzymatic multiplied immunoassay technique 
EtOH  Ethanol 
GABA  Ȗ-amino butyric acid  
GC  Gas Chromatography 
h  hours 
ICADTS International Council on Drugs and Traffic Safety 
LC  Liquid Chromatography 
M  molar, used in μM 
MS  Mass Spectrometry 
N  Number 
NCPR   Norwegian Central Population Registry  
NIPH  Norwegian Institute of Public Health 
NRAR  Norwegian Road Accident Registry 
NorPD  Norwegian Prescription Database 
RCT  Randomized Controlled Trial 
R-enantiomer R stands for rectus (Latin for right) 
RR  Relative Risk 
RT  Reaction Time 
SDLP  Standard Deviation of Lateral Position 
SEM  Standard Error of the Mean 
S-enantiomer S stands for sinister (Latin for left)
SD  Standard Deviation 
SDS  Standard Deviation Speed 
SIR  Standardized Incidence Ratio 
SOC  Stockings of Cambridge 
Z-hypnotic Z stands for zopiclone, zolpidem and zaleplon 
Zop   Zopiclone 
9 
 Contents 
0. PROLOGUE ............................................................................................................................................11
1. INTRODUCTION ...................................................................................................................................11
1.1 TRAFFIC RELATED IMPAIRMENT AND TRAFFIC ACCIDENT RISK ..........................................................11
1.2 HANDLING DUI ...................................................................................................................................13
1.3 THE USE OF HYPNOTIC DRUGS RELATED TO VEHICLE DRIVING .........................................................14
1.4 DESCRIPTIONS OF THE DRUGS IN QUESTION ........................................................................................15
1.4.1 Z-hypnotics: Zopiclone (and Zolpidem) ......................................................................................16
1.4.2 The Comparator Drugs: Ethanol, Nitrazepam and Flunitrazepam ............................................23
2.1 AIM 1 ...................................................................................................................................................25
2.2 AIM 2 ...................................................................................................................................................25
2.2 AIM 3 ...................................................................................................................................................25
3. MATERIAL AND METHODS ..............................................................................................................26
3.1 PAPER I ................................................................................................................................................26
3.1.1 Study Design ...............................................................................................................................26
3.1.2 Sources ........................................................................................................................................26
3.1.3 Study Population .........................................................................................................................26
3.1.4 Exposure .....................................................................................................................................27
3.1.5 Outcome: Standardized Incidence Ratio (SIR) ...........................................................................27
3.2 PAPER II...............................................................................................................................................28
3.2.1 Study Design ...............................................................................................................................28
3.2.2 Sources ........................................................................................................................................28
3.2.3 Study Population .........................................................................................................................28
3.2.4 Exposure .....................................................................................................................................28
3.2.5 Outcome; Impairment .................................................................................................................29
3.2.6 Data Processing ..........................................................................................................................29
3.3 PAPER III AND IV .................................................................................................................................30
3.3.1 Study design ................................................................................................................................30
3.3.2 Study Population .........................................................................................................................30
3.3.3 Study Medications .......................................................................................................................31
3.3.4 Blood drug analyses ....................................................................................................................31
3.3.5 Tests ............................................................................................................................................32
3.3.6 Assessment of Behavioral Levels ................................................................................................32
3.3.7 Assessing Impairment .................................................................................................................32
3.3.8 Data Processing ..........................................................................................................................33
3.6 ETHICAL CONSIDERATIONS .................................................................................................................34
4. SUMMARY OF RESULTS ....................................................................................................................36
4.1 AIM 1: TRAFFIC ACCIDENT RISK RELATED TO ZOPICLONE USE ..........................................................36
4.2 AIM 2: THE CONCENTRATION-EFFECT RELATIONSHIP BETWEEN ZOPICLONE AND IMPAIRMENT .........36
4.3 AIM 3: IMPAIRMENT, OBSERVED AT DIFFERENT BLOOD ZOPICLONE CONCENTRATIONS, EXPRESSED AS 
BAC ..........................................................................................................................................................38
5. DISCUSSION ...........................................................................................................................................39
5.1 METHODOLOGICAL CONSIDERATIONS .................................................................................................39
5.1.1 Paper I ........................................................................................................................................39
5.1.2 Paper II .......................................................................................................................................40
5.1.3 Paper III and IV ..........................................................................................................................42
5.2 AIM 1: TRAFFIC ACCIDENT RISK RELATED TO ZOPICLONE USE ..........................................................45
5.3 AIM 2: THE CONCENTRATION-EFFECT RELATIONSHIP BETWEEN ZOPICLONE AND IMPAIRMENT .........48
5.4 AIM 3: IMPAIRMENT, OBSERVED AT DIFFERENT BLOOD ZOPICLONE CONCENTRATIONS, EXPRESSED AS 
BAC ..........................................................................................................................................................50
10 
6. CONCLUSIONS ......................................................................................................................................54
7. SUGGESTIONS FOR FURTHER RESEARCH ..................................................................................55
8. EPILOGUE: THE PRESENT HANDLING OF DUID CASES IN NORWAY .................................56
9. ERRATA ..................................................................................................................................................57
10. REFERENCES ......................................................................................................................................58
11. APPENDIX ............................................................................................................................................68
11.1 OVERVIEW OF RELEVANT EXPERIMENTAL LITERATURE ...................................................................68
11.2 ORIGINAL PAPERS I-IV ......................................................................................................................86
11 
0. Prologue 
During the past 5 - 10 years, the Norwegian police have yearly collected breath- or blood 
samples from approximately 4,500 drivers suspected of driving under the influence (DUI) 
of alcohol. In addition, approximately the same number of drivers has yearly been 
apprehended due to the suspicion of driving under the influence of (non-alcoholic) drugs 
(DUID). More than 90 % of the blood samples collected test positive for one or more 
psychoactive drug, often revealing supra-therapeutic blood drug concentrations.  
With regards to traffic cases involving alcohol, the Norwegian Traffic Act has declared a 
legal Blood Alcohol Concentration (BAC) limit of 0.02 %, with limits for more severe 
sentencing at 0.05 % and at 0.13 %; conveying that a higher BAC represent a more 
severe crime. Similar legal limits were drawn up, and implemented as of February 1st
2012, for 20 non-alcoholic drugs, in Norway. 
Zopiclone, a medication used for treating insomnia, is one of the 20 mentioned non-
alcoholic drugs. It is one of the most commonly prescribed drugs in Norway overall. 
Nearly 1/10 of the Norwegian population receive (at least one) zopiclone prescription 
each year. 
1. Introduction 
1.1 Traffic Related Impairment and Traffic Accident Risk 
Driving a motor vehicle is a complex psychomotor task; to ensure a safe performance, the 
driver is required to occupy a broad range of skills and qualities. An estimated 90 % or 
more of traffic accidents may be linked to the driver.  
All drivers have their own baseline level of energy and alertness. Every individual’s 
baseline will naturally change due to e.g. aging, life situation and possible illness. A 
systematic review in 2005 found no evidence-based knowledge adept in determining 
medical fitness to drive. Furthermore, it has been found that drivers are unable to predict 
their own driving impairment [1]. 
Alcohol (ethanol) has often been used in experimental studies to induce traffic-related 
impairment. There are previously well documented negative effects of alcohol on 
required driving skills, in addition to an increased traffic accident risk, with an increasing 
concentration-effect relationship [2-4]. Alcohol is also the most commonly found drug 
among accident involved drivers [5]. Moskowitz and Fiorentino summarized in 2000 that 
BAC up to 0.10 % impair or influence negatively all of the following: dual attention, 
drowsiness, psychomotor skills, cognitive tasks, tracking, choice reaction time, vision, 
vigilance, perception, and simple reaction time [2]. A meta-analysis performed by 
Schnabel et al. concerning literature published  between 1990 and 2007 reported similar 
findings [4]. It should be mentioned that each of the presented skills or tests may also be 
impaired by other factors. The impaired behavior caused by alcohol consumption is not 
necessarily similar to that of other causes of traffic-related impairment, like fatigue, 
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illness or non-alcoholic drug consumption [6]. However, alcohol-induced impairment is 
the best available objective, and most reproducible, factor when defining drug-related 
impairment relevant for traffic.  
Non-alcoholic drugs have also been found to increase traffic accident risk, and to impair 
skills required for operating a motor vehicle. The previous has been observed in both 
epidemiological and experimental studies (7, 8). The evidence for traffic-related 
impairment by non-alcoholic drugs, however, is not yet as well established as it is for 
alcohol (6-8).  
Different epidemiological study designs have analyzed and described the negative impact 
of psychoactive drugs on driving, both by roadside surveys and by traffic accident risk 
studies [7,8]. In summation, epidemiological studies have been able to find evidence of 
traffic-related impairment by benzodiazepines and (to some extent by z-hypnotics) [9-
11], by cannabis [12], by amphetamine/methamphetamine [13] and by certain anti-
depressants (for elderly people) [14]. 
  
Different psychomotor tests have been used in controlled experimental studies [15]. 
Some of these tests have an obvious correlation to real-life driving performance (high 
face validity), like the on-the-road standard deviation of lateral position (SDLP) studies 
[16] or vehicle simulator tests [17]. Other experimental studies have aimed at studying 
separate skills required for driving, similar to those described for alcohol. The number of 
different studies in the field is overwhelming, making it difficult to correctly compare 
results. 
Table 1 The three recommended core levels of behavior to be measured during experimental drugged 
driving research. The table is cited from Walsh et al [8] 
Behavior levels Description Examples 
1. Automotive 
behavior 
Well learned skills Tracking, steering, vigilance or sustained attention 
2. Control behavior Maintaining distance, 
passing 
Motor performance, maneuvers, divided attention, 
perception 
3. Executive planning 
behavior 
Interactive functions with 
ongoing traffic 
Risk taking, impulsivity, information processing, 
attention, cognition, judgment 
In order to systematize the compiling literature, several attempts have been made at 
categorizing the skills required for safe driving (15, 17). One of the latest guidelines was 
initiated by the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) in 
2007 [8]. This guideline gave specific recommendations for the different types of studies 
(experimental (behavioral) studies, epidemiology and toxicology). For experimental 
research, they recommended eight issues to be focused on in particular: 1) the use of 
psychomotor tests; 2) the choice of the study population; 3) the ethical and legal issues; 
4) which drugs to be tested; 5) the specimens to correlate behavior impairment with drug 
levels; 6) the time interval for testing; 7) the issue of chronic use; 8) the choice of the 
study design.   
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Of special interest to the presented study, the ICADTS guidelines recommends three core 
levels of behavior to be measured during experimental research (table 1). The examples 
in the table below may be interpreted as a list of skills that should be well-executed to 
drive unimpaired. 
1.2 Handling DUI  
Based upon the well-established knowledge of an increased traffic accident risk related to 
the consumption of alcohol, most countries have, for several years, practiced legal limits 
of BAC within the range of 0.05 % - 0.10 % while driving. In Norway, there has been a 
legislative limit for BACs, as stated by the Norwegian Road Traffic Act, since 1936. The 
legal limit was changed from 0.05 % to 0.02 % in 2001, which is a low limit compared 
with most other countries [3,7].  
The legal driving limit for BACs of 0.02 % is considered to be mainly a politically 
determined limit, meaning that there was no scientific proof, at the time of establishment, 
of traffic-related impairment for BACs this low. Due to the low legal limit, it has been 
shown that most Norwegian drives decide to stay completely sober when planning to 
drive [18]. In contrast, the (few) drivers who still drink and drive, often do so with a high 
BAC; the mean BAC of drivers apprehended due to a suspected DUI being 
approximately 0.15 % [19].  
During the last few decades, there has been an international focus on to the problem of 
non-alcoholic drug use among drivers. Many countries have included the legal handling 
of DUID in their national laws. Legal handling of DUID may be impairment-based or 
based upon drug analyses alone [20].  
Countries practicing impairment-based legislations will often assess traffic-related 
impairments using roadside tests, performed by a police officer or by a police physician, 
in addition to blood drug analyses. Since the 1970s there has been an increased focus on 
developing a systematic procedure for evaluating suspected DUI drivers [21]. A Drug 
Evaluation and Classification (DEC) program, first developed in California, has been 
spread and used across the USA and Canada, and has even been used in some parts of 
Europe and Australasia. The DEC program involves a series of procedures, including 
several psychomotor tests and toxicological analyses [21]. The Standardized Field 
Sobriety Test is included in the DEC program, and has a high predictability, at least for 
alcohol impairment [22]. Many countries use customized Clinical Tests for Impairment 
(CTIs), performed by physicians. Such CTIs are often more sensitive to alcohol 
impairment than to other possible drugs causing impairment [23,24]. 
Drug testing may be performed roadside, by using either a breathalyzer or immunological 
tests; or the driver can be apprehended and samples (usually being blood) may be 
collected for the analysis of possible impairing drugs. Some countries have introduced 
“zero tolerance” laws, or “low concentration limits”, to prevent the use of psychoactive 
drugs while operating a vehicle. This implies that the law must define legalized drug 
concentration limits, and any concentration above the given limits will induce a sentence, 
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no matter if the driver appears impaired or not. Some countries practice legislations that 
clearly differ between prescribed medications and an illegal use (i.e. without 
prescription). In these types of cases, driving under the influence of prescribed drugs will 
require evidence of impairment for providing a sentence, while driving under the 
influence of non-prescribed drugs will not [20].   
In Norway, the police may request a blood test from any motor vehicle driver, at any 
point in time, on the suspicion of a drunk- and/or drugged driving. The police will decide 
in each case whether the blood should be analyzed for alcohol alone, or for a combination 
of alcohol and other possibly impairing drugs. The blood samples are analyzed by The 
Norwegian Institute of Public Health, (NIPH) Division of Forensic Medicine and Drug 
Abuse Research.  
An impairment-based system is followed when sentencing non-alcoholic drug-related 
impairment by Norwegian law. Until February 2012 the results from the analyzed blood 
sample, in addition to the results from the CTI and the available information on drug use 
and possible illnesses, were used as a basis for conducting an expert statement in each 
individual case of suspected drugged driving. Such statements included a presentation on 
the likelihood of impairment at the time-point of driving, and an indicative comparison of 
the non-alcoholic drug-related impairment to a BAC level. The expert statements were 
used in court as a basis for sentencing [7]. The presented system resulted in a high 
detection rate of drugged drivers, but the procedure of individual evaluations was quite 
extensive and time-consuming. The decision of introducing legal limits for non-alcoholic 
drugs in Norway was therefore made (see Epilogue).   
1.3 The Use of Hypnotic Drugs Related to Vehicle Driving 
Drivers apprehended under the suspicion of being drugged, or drunk, have been found to 
have a high prevalence of hypnotic drugs in their blood [19,24-27]. Their blood drug 
concentrations have often been documented as supra-therapeutic, indicating drug abuse 
[24-27]. A Norwegian study from 1992 found that 90 % of the samples testing positive 
for benzodiazepines contained 2-3 drugs in the same sample, and that approximately 60 
% of the samples showed illegal drugs in addition to the benzodiazepine(s) [26]. The 
most commonly detected benzodiazepine drug in the blood of suspected drugged 
Norwegian drivers has varied over the years, partly due to prescription rates [27,28] and 
availability on the illegal market. 
Before starting work on Paper I, pharmacoepidemiological studies had already stated an 
increased risk of road traffic accidents related to benzodiazepine prescriptions, in 
particular for benzodiazepines with a long half-life [10,11,29-34]. The role of possible 
confounders in most of these studies was, however, unclear. Few epidemiological studies 
had investigated traffic accident risk in relation to measured benzodiazepine 
concentrations or to the size of prescribed doses [29,33]. A case-crossover study found no 
significant increase in traffic accident risk after a hypnotic exposure in general, but 
revealed an increased risk of traffic accident involvement related to zopiclone exposure 
alone [9].  
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After the introduction of zopiclone on to the Norwegian market in 1994, a gradually 
increasing number of motor vehicle drivers, apprehended under the suspicion of impaired 
driving, have tested positive for zopiclone. This increase corresponded well to the 
increasing sales rate [28]. Similar to that of benzodiazepines and illegal drugs, z-
hypnotics were found in high blood drug concentrations among DUIs, indicating supra-
therapeutic use [25]. The NIPH included zopiclone in the routine analysis from July 
2001. Previous to July 2001, zopiclone was only analyzed on suspicion. 
Table 2 Findings in the blood of apprehended suspects (mostly vehicle drivers) in Norway between 2007 
and 2011 [19].  
Year Number of blood samples 
analyzed for non-alcoholic 
drugs 
Positivea for 
zopiclone 
N (%) 
Positivea for 
zolpidem 
N (%) 
Positivea for 
nitrazepam 
N (%) 
Positivea for 
flunitrazepam 
N (%) 
2011 9676 149 (2 %) 66 (<1 %) 272 (3 %) 59 (<1 %) 
2010 9597 135 (1 %) 52 (<1 %) 327 (3 %) 75 (<1 %) 
2009 9657 158 (2 %) 70 (<1 %) 304 (3 %) 97 (1 %) 
2008 9544 119 (1 %) 75 (<1 %) 371 (4 %) 201 (2 %) 
2007 9122 125 (1 %) 64 (<1 %) 411 (5 %) 374 (4 %) 
aAnalytical cut-offs: zopiclone 0.05 μM, zolpidem 0.05 μM, flunitrazepam 0.1 μM, nitrazepam 0.1 μM, 
diazepam 0.2 μM, alprazolam 0.03 μM, oxazepam 1 μM, midazolam 0.2 μM, clonazepam 0.1 μM, and 
fenazepam 0.1 μM. 
  
Even though z-hypnotics are commonly prescribed, it must be underlined that they are 
still not considered a main group of drugs to be found among apprehended persons 
suspected of being impaired [19,25] (table 2). 
The share of zopiclone-positive drivers, among the population of standard Norwegian 
drivers, was reported based upon findings in the oral fluid of more than 10,500 randomly 
stopped drivers between 2005 - 2006 [18]: The study revealed that zopiclone was the 
single most frequently found drug, with as many as 1.4% of random Norwegian drivers 
testing positive for zopiclone. In comparison, 1.4 % of the drivers tested positive for any 
benzodiazepine, and 0.3 % tested positive for ethanol. It should be emphasized that these 
results not necessarily reflect impairment, but based upon the findings, a thorough 
investigation into the role of zopiclone in relation to traffic accident risk was desired. 
1.4 Descriptions of the Drugs in Question  
This thesis focuses on zopiclone.  
Ethanol, in addition to the sleep medications: zolpidem, nitrazepam and flunitrazepam, 
has been used as comparator drugs in the different papers. Knowledge regarding traffic-
related impairment for these drugs will therefore briefly be summarized.  
Zopiclone has approximately 4/6 of the market share of hypnotics in Norway (calculated 
as financial turnover) [35]. Zolpidem, flunitrazepam and nitrazepam have approximately 
1/6 of the market share, when calculated together. Other drugs may also be prescribed as 
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sleep medication, e.g.: melatonin, anti-histamines, anti-psychotics, anti-depressants, and 
herbal remedies. These drugs will not be further considered here.  
In Norway, all prescribed drugs are classified into one of the following groups: A-, B-, or 
C-drugs; each with certain policies related to the classification group. Both A-drugs (e.g. 
morphine) and B-drugs (e.g. diazepam) are considered to have potential for abuse, B-
drugs are considered to be weaker than A-drugs, while C-drugs (e.g. acetaminophen) are 
considered to have no potential for abuse.  
Any prescribed drug, in Norway, known to possibly impair driving performance, has its 
packaging marked with a red triangle. This marking has been implemented by the 
authorities aiming to avoid drugged driving. All A- or B-drugs are marked with the red 
triangle, in addition to some drugs classified as C-.  
1.4.1 Z-hypnotics: Zopiclone (and Zolpidem) 
Z-hypnotics are benzodiazepine-like hypnotics with short elimination half-lives. 
Examples are zopiclone, zolpidem, and zaleplon. Zaleplon does not have a marketing 
authorization in Norway.   
1.4.1.1 History 
Zopiclone (marketed as e.g. Imovane® or Zimovane®) is the racemic mixture of R- and 
S-enantiomers, while eszopiclone (marketed as Lunesta® in the USA) only contains the 
active (S-) form.  
Zopiclone was developed and introduced by Rhône-Poulenc S.A. (now part of Sanofi-
Aventis) in the 1980s. It was promoted as a sleep inducer, and considered an 
improvement from benzodiazepines. The main arguments for the improvement were the 
faster elimination and the lower chances of residual effects, as compared with 
benzodiazepines. When zopiclone was originally introduced, it was as a racemic mixture 
only, with the strongest dose containing 7.5 mg of the active drug. In Norway, zopiclone 
was first introduced on to the market in 1994. It is now sold as 3.75 mg, 5 mg, and 7.5 
mg tablets, under the names: Imovane® (Sanofi Aventis), Zopiklon® (Mylan), and 
Zopiclone® (Actavis). 
Since 2005 the active stereoisomer, eszopiclone, has been marketed separately in some 
countries (e.g. USA), but not in Norway. The highest marketed dose of eszopiclone is 3 
mg.  
Zolpidem was introduced on to the Norwegian market in 1997. The drug is now sold in 
dosages of 5 mg and 10 mg tablets under the names: Stilnoct® (Sanofi Aventis) and 
Zolpidem® (Actavis). 
Zopiclone and zolpidem are classified as B-drugs in Norway, and are marked with a red 
triangle. 
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1.4.1.2 Pharmacoepidemiology  
Insomnia is considered to be present among 10 - 40 % of the adult population [36,37], 
and it is the only documented indication for prescribing z-hypnotics. Even though z-
hypnotics are recommended for intermittent use only, meaning no longer treatment 
period than 2 - 4 weeks, they are often prescribed for longer time periods [37-39], and 
sometimes in even higher doses than those recommended [39]. 
Similar to what has been registered in other European countries [37] , the use of z-
hypnotics has increased greatly in Norway since the early 1990s [40]. The share of the 
Norwegian population who had zopiclone prescribed at least once per year stabilized at 
around 7 % in 2007, and the percentage has remained the same since. Females constitute 
2/3 of the users [40], and use is more common among the elder [39]. As many as 30 % of 
all females, in Norway, above the age of 80, had zopiclone prescribed at least once during 
2009, compared with 21 % of all men above the age of 80 [38]. The higher use among the 
older females is probably related to a higher prevalence of insomnia among females 
compared with men [41], in addition to a higher prevalence of insomnia among the elder 
compared with younger people.     
Z-hypnotics have taken over, and hold the largest share of the world-wide hypnotic drug 
market, during the past 1 - 2 decades [37,40]. The prescribing patterns seem to differ 
between countries, and even within a country [37,42], meaning that the “main” hypnotic 
drug prescribed will vary from place to place [37,43]. In the early 2000s, zolpidem was 
approximately two times as commonly prescribed as zopiclone, worldwide [43]. In 
Norway, zopiclone is prescribed more than six times as often as zolpidem [38]. 
Few studies have considered the abuse liability of z-hypnotic drugs. Due to the many 
similarities with benzodiazepines, some general awareness should be sought before 
prescribing a z-hypnotic drug to drug addict. A few reports concerning the abuse of 
zopiclone, or zolpidem, confirms a certain risk of abusing z-hypnotics, at least among 
people with a history of drug- or alcohol abuse. The abuse liability is, however, claimed 
to be lower for z-hypnotics than for benzodiazepines [43,44]. There is sparse information 
about an eventual illegal market for zopiclone. The Norwegian police has reported that 16 
% of the approximately 32,000 incidents of illegal drugs seized in 2011 contained 
benzodiazepines [45]. Interestingly, z-hypnotics were not even mentioned in the report, 
indicating that z-hypnotics probably constitute a very low share of the Norwegian illegal 
market.    
1.4.1.3 Pharmacokinetics 
Zopiclone is administered orally as tablets. It is rapidly absorbed, with the Cmax being 
reached within 0.5 - 4 hours after intake, and usually within 1 hour [46,47]. 
Bioavailability, after oral intake, is reported at around 80 % [47,48]. The Cmax after the 
oral intake of 7.5 mg of zopiclone has been reported to be between 54 - 86 μg/L [47,49]. 
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Patients with a liver- or a renal insufficiency, have been shown to have a higher Cmax
value [48]. About 45 % of zopiclone in plasma is bound to proteins [46]. 
Zopiclone is metabolized in the liver by oxidation and demethylation. The formation of 
N-oxide zopiclone (which has sleep inducing properties, though lower than the parent 
drug), and N-desmethyl zopiclone (which has some anxiolytic properties), is mainly 
metabolized by CYP3A4. In addition, CYP2C8 is involved in the formation of N-
desmethyl zopiclone [50]. N-oxide zopiclone, N-desmethyl zopiclone, and unchanged 
zopiclone (<7 % of the dosage taken) are excreted via the urine [47]. The terminal half-
life has been reported to be between 3.5 - 6.6 hours [47,49], and is severely prolonged for 
patients with liver failure and for elderly people [48]. Based upon the altered 
pharmacokinetics, older people, and patients with an organ failure, are advised to 
consume lower doses. 
Concomitant treatment with CYP3A4 inducers (e.g. rifampicin) has been proven to 
reduce the blood zopiclone concentration [51], while concomitant treatment with 
CYP3A4 inhibitors (e.g. macrolides or grapefruit juice) may increase the blood zopiclone 
concentration [46]. The CYP2C8 inhibitor, gemfibrozil, has not been shown to increase 
the blood zopiclone concentration [46].  
Clinical trials have found that an every day intake of 7.5 mg of zopiclone, for 14 days, 
does not significantly alter the Cmax values. Only slight accumulations have been 
observed (34, 38).   
Like zopiclone, zolpidem has a high bioavailability (70 %), and is metabolized by 
CYP3A4 [52]. Zolpidem has a terminal half-life of approximately 1.5 - 4.5 hours [49,53].  
1.4.1.4 Pharmacodynamics 
Zopiclone provide its effects by binding to the benzodiazepine receptors (Ȧ or BZ), 
located on the Ȗ-amino butyro acid (GABA)A-receptor complex in the central nervous 
system. Two central benzodiazepine receptors have been identified: BZ1 and BZ2  
[54,55]. The BZ1- and BZ2 receptors consist of different subunits: The BZ1-receptor 
contains Į1 subunits, while the BZ2-receptors are heterogeneous and contain either Į2, Į3 
or Į5 subunits [56]. The binding to the subunit on the BZ-receptor mediates the specific 
effect. The BZ1-receptor is known to be involved in mechanisms related to sleep- and 
wakefulness, while the BZ2-receptor has been demonstrated to mediate cognitive-, 
anxiolytic-, memory- and psychomotor functions [54].  
Zolpidem is found to bind specifically to the BZ1-receptors [43,52]. Some researchers 
have claimed that zopiclone, like zolpidem, also binds specifically to the BZ1-receptor, 
and thereby mediating less unwanted side effects compared with benzodiazepines [57]. 
The previous is yet to be verified in vivo [58,59]. Intake of zopiclone leads to much of 
the same effects as benzodiazepines: sleepiness/drowsiness, muscle relaxation, and 
amnesia, in addition to having anxiolytic- and anti-convulsive effects [49], with a liability 
for abuse [56]. It should be noted that animal studies have suggested that the BZ1-
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receptor is additionally involved in motor performance and in mediating abuse potential 
[54].    
Sleep induction is the only indication for prescribing z-hypnotics. Zopiclone is proven to 
induce sleep, and maintain sleep quality, at dosages of 5 and 7.5 mg [49]. There are 
different opinions regarding zopiclone’s residual effects (see Section 1.4.1.6). Some 
researchers claim that there is a low probability of residual effects if not exceeding the 
recommended dose of 7.5 mg [60,61]. Tolerance is reported to be unlikely [62,63]. 
However, there is evidence that long-term use of zopiclone, among patients suffering 
from insomnia, is non-effective in treating insomnia, and that cognitive therapy has a 
greater clinical effect for this group of patients [64,65]. The most common side effects 
reported for zopiclone are: bitter taste, dry mouth, drowsiness, and nightmares [49]. 
For zolpidem, a bed-time administration of the recommended dosage (5 - 10 mg) will not 
normally cause a residual sedation, nor impair the psychomotor performance during the 
following day [49,66]. The most common side effects are: dizziness, drowsiness, 
headache, and nausea. An increasing number of case report has related the intake of 
zolpidem to different incidents of parasomnias, describing complex behaviors like: sleep 
eating, sleep cooking, sleep driving etc. [67]. Although the long-term use of zolpidem is 
not recommended, several studies have found that zolpidem can maintain its 
effectiveness for up to several weeks [49].  
A meta-analysis, aimed at comparing different hypnotic agents, did not find any 
convincing differences in wanted - or unwanted effects between zopiclone and zolpidem, 
nor between z-hypnotics and benzodiazepines [59].  
  
1.4.1.5 Current Knowledge on Zopiclone and Traffic Accident Risk
Before commencing the presented PhD study, quite many epidemiological studies had 
investigated traffic accident risk related to benzodiazepine exposure [9-11,29-34]. In 
these studies benzodiazepines were investigated together, not differentiating between the 
specific drugs.  
Barbone et al. performed a within-person case-crossover study in 1998, aiming to 
investigate tricyclic antidepressant drugs, benzodiazepines, selective serotonin-reuptake 
inhibitors or other drugs (mainly major tranquillizers); and reported an increased traffic 
accident risk for zopiclone and for anxiolytic benzodiazepines [9]. The N for zopiclone 
was, however, quite low, with only 14 traffic accidents related to zopiclone exposure. 
The results were still very interesting, in particular because the case-crossover design 
reduced the chance of confounding effects.  
After publishing Paper I, other studies have found various degrees of increased traffic 
accident risk related to z-hypnotic exposure [13,68,69] (see Section 5.2).
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1.4.1.6 Traffic Related Impairment: Current Knowledge from 
Experimental studies 
Experimental Studies on Zopiclone Listed in the Appendix 
The appendix displays 44 experimental studies (47 articles) on zopiclone and traffic-
related impairment. These studies have been retrieved from literature search in Pubmed, 
MEDLINE and EMBASE, using relevant search words (as described in the Appendix), as 
of December 2011. Only objective tests on psychomotor impairment were considered. 
Papers inherent were not included. 
SDLP
Memory / Learning
Substitution tests
Attention / Cognition
Coordination
Balance CTI 
Divided attention
Vision 
CRT
Tracking
RT
Figure 1: The frequency of use of the different tests included in the 44 experimental studies on the effects 
following zopiclone intake. Only the most commonly used tests are named at the figure 
Healthy young volunteers were used as a study population in 34 of the 44 experimental 
studies (77 %). Only 4 studies were performed on patients suffering from insomnia [70-
73]. Figure 1 shows the distribution of the different tests used in the experimental studies, 
as listed in the Appendix. The figure reveals that a wide range of tests have been used to 
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Figure 2: The distribution of measured blood zopiclone concentrations in previous RCTs after an intake of 
7.5 mg of zopiclone. Mean values are shown for each group of healthy volunteers, related to time after 
intake. For the studies by Allain et al. and by Paul et al., the mean results were retrieved from figures
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investigate zopiclone. Reaction time, tests related to learning or memory, and substitution 
tests were among the most frequently applied.  
For 10 out of the 44 experimental studies, blood zopiclone concentrations were measured 
during the study [74-83]. One of these ten studies did not report the analyzed blood 
zopiclone concentrations in the article [83]. The remaining nine studies reported the mean 
blood zopiclone concentrations for the groups of volunteers. The measured mean values 
are presented in Figure 2. As illustrated, the mean blood zopiclone concentrations varied 
widely between the different studies, even though the zopiclone dose was 7.5 mg for all 
studies. In general, the measured blood zopiclone concentrations were lower, for many of 
the studies, than what would be expected from other studies focusing on 
pharmacokinetics. The Cmax following 7.5 mg of zopiclone has been reported to lie 
between 54 - 86 μg/L [47,49]. 
Table 3: A view of the different tests used for measuring impairment in the 44 experimental studies listed 
in the Appendix. The table illustrates how often the tests were not significantly impaired, and for studies 
demonstrating significant impairment: how long time after intake a significant impairment was 
documented. Only results after intake of 7.5 mg of zopiclone are included 
Tests (Number of 
studies using the test) 
Number of studies 
where the test was not 
significantly impaired 
after intake (%) 
Number of studies where the test was impaired after 
intake related to the latest point-of-time after intake 
still demonstrating impairment (%): 
> 0h  2h > 2h  5h >5h  9h > 9h  13h 
SDLPa (9) 1 (11%)    8 (89%) 
SDSb (4) 2 (50%)    2 (50%) 
Stop signal (2) 1 (50%)    1 (50%) 
Tracking (14) 7 (50%) 3 (21%) 1 (7%)  3 (21%) 
RTc (18) 8 (44%) 2 (11%) 3 (17%) 2 (11%) 3 (17%) 
CRTd (8) 5 (63%) 2 (25%)   1 (13%) 
Letter cancellation (3) 3 (100%)     
Errors (2) 1 (50%)    1 (50%) 
Dual attention (8) 4 (50%)  1 (13%)  3 (38%) 
Vision (16) 8 (50%) 3 (19%) 4 (25%) 1 (6%)  
Symbol copy test (5) 4 (80%)    1 (20%) 
Memory/learning (18) 7 (39%) 3 (17%) 2 (11%) 1 (6%) 5 (28%) 
 DSSTe (17) 6 (35%) 2 (12%) 3 (18%) 4 (24%) 2 (12%) 
Attention/cognition (7) 2 (29%) 2 (28%) 1 (14%) 1 (14%) 1 (14%) 
Tapping test (3) 2 (67%)    1 (33%) 
Coordination (6) 4 (67%)  1 (17%) 1 (17%)  
Balance (12) 4 (33%) 3 (25%) 3 (25%) 2 (17%)  
CTIf (2)  2 (100%)    
aStandard Deviation of Lateral Position 
bStandard Deviation Speed 
cReaction Time 
dChoice Reaction Time  
eDigit Symbol Substitution Test 
fClinical Test for Impairment 
All 44 experimental studies related impairment to time after zopiclone intake, presenting 
mean impairment values for the groups of study populations. Significant impairment was 
defined as a significant difference between: mean performances after drug and placebo at 
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certain point-of-times after drug and placebo administration. Among the studies listed in 
the Appendix, none considered individual impairment, dichotomized as impaired or not 
impaired for each single observation.  
Table 3 reviews different tests used in experimental studies on zopiclone effects in 
relation to time after intake still documenting impairment. Only the latest point-of-time, 
with significant impairment, was registered. Different time-points for measuring  
Table 4: Studies relating BAC values to impairment following intake of 7.5 mg zopiclone 
References Used tests Mean blood zopiclone 
concentrations 
compared to mean 
BACs 
Time after intake of 7.5 mg 
zopiclone compared to time 
after intake of 0.3-0.8 g/kg 
ethanol (EtOH) 
Kuitunen et al. 1990/1994 
[23,78]b 
0.8 g/kg ethanol given. 
Mean blood drug 
concentrations measured at 
1.5 h and 4.5 h after intake.
Attention, Body 
sway, Tracking 
errors, DSST and 
Vision 
37 μg/L § 0.08 % 
~23 μg/L § ~0.04 % 
1,5 h  zop § 1,5 h EtOH 
3 h  zop § 3 h EtOH  
4,5 h  zop § 4,5 h EtOH 
Reaction time 37 μg/L > 0.08 % 
~23 μg/L > ~0.04 % 
1.5 h zop > 1.5 h EtOH 
3 h zop > 3 h EtOH 
CTI ~37 μg/L < ~0.08 % 
~23 μg/L  ~0.04 % 
2 h zop < 2 h EtOH  
5 h zop  5 h EtOH 
Mamelak et al. [71]a, b  
0.5 g/kg ethanol given. 
Memory, RT, 
Tracking, DSST, 
Balance 
(11 h zop) < 0.07 %  
(11 h zop) < 0.04 %  
11 h zop < 1 h EtOH 
11 h zop < ~2.5 h EtOH 
Vermeeren et al. [84]a, b
Approximately 0.3 g/kg 
ethanol given. 
SDLP (10 h zop) > 0.04 %  10 h zop > 2 h EtOH  
Word learning, 
Tracking, Dual 
attention 
(9 h zop) > 0.04 %  9 h zop > 1 h EtOH  
Mattila et al. 1997/1998 
[77,85] 
0.65 + 0.35 g/kg ethanol 
given. Mean blood drug 
concentrations measured at 
1.5 h, 4 h and 5.5 h after 
(the first) intake. 
Tracking errors  ~93 μg/L > ~0.08 % 
~71 μg/L < ~0.09 % 
~48 μg/L § ~0.06  
1 h zop > 1 h EtOH 
3.5 h zop < 3.5 h EtOH 
5 h zop § 5 h EtOH 
Substitution tests  ~93 μg/L § ~0.08 % 
~71 μg/L § ~0.09 % 
~48 μg/L § ~0.06  
1 h zop § 1 h EtOH 
3.5 h zop § 3.5 h EtOH 
5 h zop § 5 h EtOH 
Reaction time ~93 μg/L >> ~0.08 % 
~71 μg/L > ~0.09 % 
~48 μg/L  ~0.06 % 
1 h zop >> 1 h EtOH 
3.5 h zop > 3.5 h EtOH 
5 h zop  5 h EtOH 
Body balance  ~93 μg/L § ~0.08 % 
~71 μg/L  ~0.09 % 
~48 μg/L  ~0.06 % 
1 h zop § 1 h EtOH 
3.5 h zop  3.5 h EtOH 
5 h zop  5 h EtOH 
Memory ~93 μg/L §  ~0.08 % 1.5 h zop § 1.5 h EtOH  
aBlood zopiclone concentrations not measured 
bBlood alcohol concentration measured by breath test
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impairment, and different tests applied, make it a complex task to sum up the overall test 
results. Some of the studies have aimed to investigate residual effects (often using 
sensitive tests), while some have aimed to investigate impairment during the first few 
hours after intake (often using less sensitive tests).  
In 4 out of the 44 experimental studies, ethanol was used as a comparator drug for 
zopiclone impairment [23,71,77,78,84,85]. (The 4 studies were reported in 6 
manuscripts.) Viewed together, these studies give an incomplete picture of comparable 
BAC values (Table 4). 
DRUID Meta-Analysis  
A meta-analysis of experimental studies on DUID research, as conducted between 1994-
2006, was recently carried out [86], being part of the European DRUID program (Driving 
Under the Influence-Program). Impairment after oral drug intake, for each of the 33 
possible impairing drugs, was related to time after intake, or related to blood drug 
concentrations. In cases where blood drug concentrations were not measured, an 
estimation based upon pharmacokinetic studies was performed. Drug impairment was 
further related to ethanol impairment based upon another DRUID meta-analysis on the 
effects of ethanol [4] (see section 1.4.2).  
For zopiclone, 21 studies on the experimental effects on healthy volunteers were included 
in the meta-analysis. None of the studies in the DRUID report considered a higher 
zopiclone intake than 7.5 mg. The 21 experimental studies concluded on relevant 
impairment (higher than corresponding to BAC 0.03 %) up to 11 hours after the intake of 
7.5 mg of zopiclone. Slightly more than 50 % of the effects measured at around 1 h after 
the intake of 7.5 mg of zopiclone were significantly impaired, corresponding to a BAC 
level of around 0.08 %. A higher percentage of the effects were significantly impaired at 
around 4 hours after intake. The method did not consider the sensitivity of the different 
impairment tests at the certain points-of-time after intake. Neither did the meta-analysis 
consider the matter of acute tolerance developing for zopiclone.  
For zolpidem, the DRUID meta-analysis reported that more than 20 % of the effects were 
significantly impaired by 8 hours after the intake of 20 mg, and by 5 hours after the 
intake of 10 mg.   
1.4.2 The Comparator Drugs: Ethanol, Nitrazepam and Flunitrazepam  
Another meta-analysis, as part of the European DRUID program, was recently performed 
[4]. This report considered studies on ethanol published between 1990 and 2007. The 
meta-analysis aimed to provide a scientific basis in relation to traffic-related impairing 
effects, and to use the results as a reference function for the impairing effects of non-
alcohol drugs in the DRUID meta-analysis on non-alcohol drugs. The report registered 
significant effects, related to BACs (measured or estimated values), on various 
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psychomotor tests, used in experimental studies. Nearly 3000 findings were reported, 
related to BACs between 0.01 % and 0.12 %. The meta-analysis confirmed previous 
knowledge on a positive concentration-effect relationship for ethanol, and found that 
simple tasks were less impaired than complex tasks, for low BACs. For high BACs, the 
complexity of the tasks did not matter [4].  Interestingly, the meta-analysis found no 
evidence for an acute tolerance development to ethanol. Based upon the DRUID meta-
analysis for ethanol, it was estimated that BACs below 0.03 % corresponded to less than 
15 % impaired observations, and that BACs above 0.08 % corresponded to more than 50 
%  impaired effects [86].  
The report by Moskowitz and Fiorentino on BACs, found that some studies show 
significant impairment below 0.05 % BAC, most studies at 0.05 % BAC, and as many as 
94 % of studies above 0.08 % BAC [2]. As expected, tests considered the most sensitive 
have shown impairment at low BACs, while less sensitive tests reveal impairment only at 
higher BACs. Driving, flying, and divided attention, all have been found sensitive 
(impairment even below 0.01 %), while tests such as simple reaction time and critical 
flicker fusion test (CFF) have been found less sensitive. Ethanol is also proven to be a 
cause of traffic accidents, in a positive concentration-effect relationship [3]. All in all, 
ethanol is therefore considered feasible as a positive control in experimental DUID 
research [8].  
Flunitrazepam and nitrazepam are benzodiazepine hypnotics marketed in Norway; both 
having long terminal half-lives. It has been documented that benzodiazepines, in general, 
are possible impairing drugs, also commonly abused among polydrug users [37]. 
Flunitrazepam has received some negative attention because of abuse of Rohypnol 
[87,88]. Based upon the negative attention, and the police’s disclosure of illegal import, 
Rohypnol was made an A-classified drug in 2003 in Norway, markedly lowering sales 
rates and findings of the drug in the blood samples from suspected drugged drivers [19]. 
The manufacturer decided to withdraw Rohypnol® from the market in 2004 [89].  
Nitrazepam has been considered a less “dangerous” drug, although there is, in fact, no 
evidence of such a difference based upon the pharmacological properties. A recent 
Norwegian study found that nitrazepam was the benzodiazepine most often prescribed in 
conjunction with other benzodiazepines [90]. 
The recent DRUID meta-analysis on non-alcohol drugs followed a similar design to the 
DRUID ethanol meta-analysis [86]. The meta-analysis aimed to investigate possible 
traffic-related impairment for 33 possibly impairing drugs. For flunitrazepam, a linear 
relationship between percentage of impaired effects and (estimated) blood flunitrazepam 
concentrations was found. For nitrazepam, the findings were not equally clear. Former 
studies have, however, found evidence of traffic-related impairment following 
nitrazepam, as well as flunitrazepam, based upon both experimental- and observational 
studies [7]. 
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2. Aims
The aim was to investigate the scientific basis for introducing legal limits for zopiclone 
related to traffic. A scientific basis was postulated to include: a) demonstration of an 
increased traffic accident risk related to the use of zopiclone, and b) a positive 
concentration-effect relationship between blood zopiclone concentrations and traffic-
related impairment, comparable to what had previously been found for ethanol.  
We aimed at further exploring the following three questions: 
2.1 Aim 1 
Does use of zopiclone increase traffic accident risk? (Paper I) 
2.2 Aim 2 
Is there a positive concentration-effect relationship between zopiclone 
concentrations and traffic-related impairment? (Papers II, III and IV)  
2.2 Aim 3 
Are there any fundamental differences between the concentration-effect 
relationships (as mentioned under Aim 2) for zopiclone and for ethanol? (Papers 
II, III and IV) 
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3. Material and Methods 
3.1 Paper I 
3.1.1 Study Design 
Paper I is an observational study. We used a cohort design.  
3.1.2 Sources 
Three sources of data were used: the Norwegian Prescription Database (NorPD), the 
Norwegian Road Accident Registry (NRAR), and the Norwegian Central Population 
Registry (NCPR). 
The NorPD is a research database that captures all dispensed prescriptions from 
Norwegian pharmacies as of January 2004 [91]. The database only contains information 
on prescriptions in relation to ambulatory treatment; it does not include prescriptions 
given to hospitalized patients. As an example, in 2007, 68 % of the Norwegian 
population were registered as having dispensed at least one prescribed medicine [92]. The 
registry includes information on the patient (pseudonymous identification numbers, their 
residence etc.), the prescriber (their speciality, their gender, their identification number 
etc.), the drug (the ATC (Anatomical Therapeutic Chemical) code, the dose, the number 
of tablets etc.), and the pharmacy dispensing the drug (the county in which it is placed 
etc.) [92]. Pharmacy records of dispensed drugs are electronically transferred to NIPH 
through Statistics Norway to ensure confidentiality. Statistics Norway replaces both the 
patient’s identification number and the prescriber’s identification number with 
pseudonymous numbers.  
The NRAR provides information on motor vehicle accidents involving personal injuries 
on Norwegian roads [93]. Any traffic accident with a personal injury in Norway is 
required to be registered by the police, who report to the NRAR. NRAR does not provide 
information as to whether the driver was responsible for the accident, nor as to the 
severity of the injury. Less severe accidents and injuries are often not reported to the 
police, and will therefore remain unregistered by the NRAR.  
The NCPR contains information on all Norwegian inhabitants, e.g. their name and their 
unique identification number, as assigned to each individual living in Norway. Unique 
identification numbers allows an assured coupling between the registries. The NCPR is 
administered by the Norwegian Directorate of Taxes.
3.1.3 Study Population 
Paper I studied the entire Norwegian population aged 18 - 69 during the time period: 
January 2004 - October 2006 (including 3.1 million people). The population was 
stratified into groups by age and gender. 
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3.1.4 Exposure  
Paper I defined hypnotic exposure as having dispensed a hypnotic prescription for one of 
the following drugs: zopiclone, zolpidem, nitrazepam or flunitrazepam; further 
differentiating between the first 7 days and the first 14 days after dispensing, where the 
first day was defined as the day after the date of the dispensation.  
SIR was calculated in different ways: 
a) Concurrent prescriptions for other medications were not considered 
b) Those with concurrent additional psychoactive drug prescriptions were excluded 
c) Only incidental hypnotic drug users were included (180 day washout)   
d) Only drivers, who, during the study period, had been involved in accident(s), as 
registered in the NRAR, were considered (case-crossover: results not shown in 
Paper 1) 
3.1.5 Outcome: Standardized Incidence Ratio (SIR) 
The SIR is the ratio between the number of traffic accidents in the exposed person-time 
and the non-exposed person-time (Figure 3).  
Figure 3: An illustration of the exposed- and non-exposed person-time. Each line represents an individual. 
The stars represent traffic accidents and the oval circles represent the subject dispensing one of the 
hypnotic drugs in question. The oval circles are followed by grey lines, representing exposed person-time. 
The black lines represent non-exposed person-time 
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3.2 Paper II 
3.2.1 Study Design 
Paper II is an observational, cross-sectional study based upon an internal data source at 
the NIPH.   
3.2.2 Sources 
The study is based upon the Apprehended Driver Registry located at the Division of 
Forensic Medicine and Drug Research. Since December 2000 these data have been stored 
in a computer program by the name of StarLIMS, which is also an integrated laboratory 
management system (STARLIMS Corporation, 4000 Hollywood FL 33021). 
Approximately 82 % of the cases requested by the police to be analyzed are 
apprehensions due to suspicious driving or due to traffic accident involvement (data 
retrieved from StarLIMS Database regarding the years 2007-2011). The remaining 18 % 
constitute cases involving other types of crimes, such as assault and battery.  
The CTI results, and the analytical results, were retrieved from the StarLIMS database. 
StarLIMS contains information on all cases where the Norwegian police request a blood 
drug analysis due to a suspected criminal offence. The StarLIMS database contains 
information on the incident (e.g. the place, the time point, the reason for the requested 
blood sampling), the suspect (e.g. the name, the gender), the analytical results, and 
information on- and the outcomes of the CTI. A standardized procedure, related to 
forensic toxicology, was thoroughly followed with regards to the chain of custody and the 
analytical procedures for all of the included blood samples. 
3.2.3 Study Population 
The population of drivers and other apprehended criminal suspects, during the time 
period between 2000 and 2007, where the police requested blood drug analyses (N = 
35,756), were investigated. For practical reasons, the study population was called 
apprehended drivers throughout Paper II. Former research has shown that this population 
includes for the most part a marginalized subpopulation of Norwegian drivers, with high 
blood drug concentrations and with high DUI recidivism rates [94] and mortality [95].  
3.2.4 Exposure  
The blood samples were screened for the most common non-alcoholic drugs of abuse, in 
addition to alcohol. Samples revealing other drugs than zopiclone, zolpidem or ethanol, 
as confirmed in blood, and samples containing more than one drug, were excluded.   
The screening used a combination of enzymatic- (alcohol), enzyme multiplied 
immunoassay technique (EMIT)-, and liquid chromatography / mass spectrometry 
(LC/MS) methods. Approximately twenty-five potentially impairing non-alcoholic drugs 
were routinely screened for, including: amphetamines, a number of benzodiazepines, 
cannabis, cocaine, and opiates. In addition, carisoprodol, meprobamate, methadone, 
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carbamazepine, and phenobarbital were routinely screened for in samples received after 
May 2001. Z-hypnotics were routinely screened for in samples received after June 2001. 
All positive screening results were confirmed. 
The confirmation analyses were performed by LC/MS for zopiclone and zolpidem, and 
by headspace gas chromatography (GC) for alcohol [96]. The cut-off value for zopiclone 
was 19 μg/L, 15 μg/L for zolpidem, and 0.004 % for ethanol.  
3.2.5 Outcome; Impairment 
In those cases where the police suspect a driver of being under the influence of non-
alcoholic drugs, a police physician will perform a CTI shortly after the apprehension. The 
Norwegian CTI consists of three separate parts: First, the physician obtains information 
on current and former drug use, in addition to any other type of information which may 
explain the suspected impairment (e.g. diseases, disabilities etc.). Second, the physician 
will instruct the apprehended to perform a set of subtest, recording the results on a 
standardized form. Examples of subtests are: motor coordination, cognitive functions, 
and alertness. In addition, the physician must evaluate certain signs, such as: appearance. 
All together, the CTI includes twenty-five subtests and signs [97]. Third, the physician 
must make a conclusion as to whether the apprehended appears drug impaired or not 
impaired (selecting between five choices: not impaired – slightly impaired – moderately 
impaired – highly impaired – not possible to conclude on impairment). The conclusions 
are dichotomized in Paper II to: “impaired” or “not impaired”.   
The Norwegian CTI is performed by different local physicians, some of whom rarely 
administering the test. The CTI was originally created to reveal alcohol impairment, but 
has later been modified to cover some of the signs of central nervous system (CNS) 
stimulant- or depressant consumption (e.g. time-perception and restless appearance). 
Positive relationships between CTI assessed impairment and blood drug concentrations 
have been documented for ethanol [24,98], carisoprodol [99], codeine [100], Δ-9-
tetrahydrocannabinol [101], (meth-)amphetamine [102], and morphine/morphine-6-
glucuronide [103]. In accordance with previous literature on impairment [3,23], the 
strongest relationship between blood drug concentrations and impairment, as assessed by 
the CTI, is documented for ethanol. 
3.2.6 Data Processing 
3.2.6.1 Data Programs
Statistical analyses were calculated using Excel version 2003 and SPSS versions 14.  
Sigmaplot version 9 (SYSTAT software Inc.) was used to make figures.  
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3.2.6.2 Statistic tests
A Pearson’s test was used for calculating differences between the shares of impaired 
observations related to the different drug concentration. Fisher’s Exact test was used for 
calculating differences when the number of observations was low.  
Mann Whitney U-test was used for calculating differences between the groups.  
A binary regression model was used, where impaired was the dependent variable, and 
blood drug concentration, age, and gender all were independent variables. 95 % CI 
(confidence intervals) were used.  
3.3 Paper III and IV 
3.3.1 Study design 
A double blind, randomized, controlled trial (RCT) was used to investigate 16 volunteers 
with respect to the effects of zopiclone and ethanol, in a 4-way crossover setup.  
3.3.2 Study Population 
A small pilot was performed in advance of the actual study to determine the number of 
required volunteers. The pilot included two volunteers, which were each given 50 g of 
alcohol. The volunteers performed only the Connors Continuous Performance Test (CPT) 
test, because standard errors of measurements for different age-groups and gender were 
already provided in the CPT manual. The values obtained from the different test 
components were used to calculate the standardized difference based upon the Altman’s 
nomogram, with P=0.05 and 80 % power: The results indicating it necessary to include at 
least 10 test subjects in the study, this allowing the determination of a true differences for 
at least two CPT test components. Consequently, an attempt was made at recruiting 15 - 
20 volunteers. 
  
16 healthy male volunteers with a median age of 23.5 years (range 20 - 28), and a median 
body weight of 76.5 kg (range 69 - 88), were included in the study. The volunteers were 
required to refrain from alcohol consumption during the final 72 hours before each 
session, in addition to refraining from any type of medication during the preceding week. 
Exclusion criteria were: 
1. History of- or current drug/alcohol abuse 
2. Former abnormal reaction to any type of hypnotic drug 
3. Intake of zopiclone during the 3 months previous to the study 
4. Regular (daily) intake of any prescribed drug 
5. History of severe allergic disease 
6. History of significant mental, cardiovascular, renal, or hepatic disorder, or any 
other significant disease as judged by the investigator 
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7. Positive pre-session urine sample (confirmation analysis) for any of the following 
substances: ethanol, benzodiazepines, zopiclone, zolpidem, tetrahydrocannabinol, 
cocaine, amphetamine, methamphetamine, morphine or codeine 
3.3.3 Study Medications  
Four different study medications were provided for the RCT: 5 and 10 mg tablets of 
zopiclone, 50 g of ethanol and placebo. The manufacture, the blinding procedure, and the 
packaging of the studied drugs are described in detail in Paper III.  
Figure 4: Study medications: two capsules and one liquid drink were given to each subject, each morning, 
on each study day 
Preceding the study, another small pilot was conducted using four volunteers. The aim 
was to detect the expected blood zopiclone concentration levels, after the intake of 
zopiclone, at the previously decided time-points for blood sampling. Another aim was to 
investigate if blood zopiclone concentration levels differed after capsule- or original 
tablet intake. Lower concentrations than expected was found for zopiclone in blood, after 
the consumption of both capsules and tablets, as compared with results from former 
studies [47]. No difference was found between blood zopiclone concentrations with 
capsular- and original tablet form. 
3.3.4 Blood drug analyses  
The quantifications of zopiclone and ethanol in blood were performed by HPLC-MS, and 
by headspace GC analysis, respectively (see Paper III). The limits of quantification were 
7 μg/L for zopiclone and 0.004 % for ethanol.  
All blood samples were stored at 4 ºC immediately after sampling. Analyses were started 
within 24 hours. 
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3.3.5 Tests 
The aim was to use psychomotor tests that covered all three levels of behavior; 
Automotive, Control and Executive Planning Behavior [8]. In addition, the tests had to 
suit the study design, the localities and the time frames. A description for each of the 
selected tests is presented in Table 5.  
Table 5: Tests chosen for the RCT 
Test Short description Test 
duration 
Explanation for the choice 
SOC Measures executive planning and motor 
control 
10 min Described as quite similar to the test by the 
name of: Tower of London, which is used 
in DUI studies 
CRT Measures response speed and ability to 
make correct decisions quickly 
7 min Well known and used in DUI studies 
CPT Measures attention: clinically used 
among attention deficit hyperactivity 
disorder patients 
14 min  Quite long duration. Appeared sensitive to 
drug effects 
3.3.6 Assessment of Behavioral Levels 
Twenty-three test components (4 + 7 + 12), from the three selected computerized tests, 
were available. The aim was to include representative test components, and not to use any 
measured parameter more than once (e.g. some test components were registered as both 
median and mean). The descriptions of each test component, as given in the test manuals, 
were used as a basis for the selection. 
Fifteen test components were deemed appropriate and categorized into three behavioral 
levels, based upon the descriptions given in the test manuals related to the Talloire report 
[8] (Table 6).  
3.3.7 Assessing Impairment 
Paper III used placebo as a reference when calculating possible impairment. Mean values 
were calculated, at each point-in-time examined after intake, for each of the single test 
components. Any significant deterioration between the mean performances, as compared 
with placebo, was defined as impairment.  
Paper IV dichotomized each of the volunteer’s single psychomotor test performances, 
after being compared with the volunteer’s own baseline performance, into either impaired 
or not impaired. The baseline performance was defined for every single test component, 
for each of the 16 volunteers. The values were given by using the range of four baseline 
performances, and adding/subtracting 5 % off the mean baseline test performance. Any 
test result above the range of individual baseline performance +/- 5 % was defined as 
impaired, while any test result similar as, or below, the range of individual baseline 
performance +/- 5 %, was defined as not impaired. 
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Table 6: A description of all of the included test components, divided by behavioral levels  
Level 1: Automative behaviors a 
CRT rt var The standard deviation of the reaction time. Measured consistency of reaction 
time 
CPT rt var The standard error of reaction time. Measured consistency of reaction time 
CRT omis Omissions: the number of targets to which the volunteer did not respond. 
Measured automative behavior 
CPT omis Omissions: the number of targets to which the volunteer did not respond. 
Measured automative behavior 
CPT alert The slope of change in reaction time over the 6 blocks. Measured the ability to 
stay alert. A vigilance measure 
CPT adjust The slope of change in reaction time related to the inter stimulus intervals. A 
positive slope indicated a slower reaction time as the inter stimulus interval 
increased. Measured the ability to adjust to the presented speed 
Level 2: Control Behaviors a
SOC r time Reaction time: the volunteers’ speed of movement from initial move to last 
move for the 5 moves-problems 
CRT r time Reaction time: the mean latency from stimulus appearance to button press 
CPT r time Reaction time: the mean response time for all 6 blocks 
CRT pers Perseverations: the percentage of trials the volunteer responded too fast. 
Measured perception and motor performance 
CPT pers Perseverations: the number of times the volunteer responded too fast.  Measured 
perception and motor performance 
Level 3: Executive Planning a
SOC plan  The mean time to select the first ball in the 5 moves problems. Measured 
planning and cognition 
SOC incor How many times the volunteer not completed the problems in the minimum 
possible number of moves. Measured information processing, attention and 
cognition. 
CRT com Commissions: the percentage of trials the volunteer pressed the wrong button. 
Measured information processing and attention  
CPT com Commissions: the number of times the volunteer responded to a non-target. 
Measured impulse control and attention 
a [8]  
3.3.8 Data Processing 
3.3.8.1 Data Programs
Statistical analyses were calculated using Excel version 2003 and SPSS versions 17.  
Sigmaplot version 12 (SYSTAT software Inc.) was used to make figures.  
The software belonging to the computerized tests SOC, CRT and CPT converted the 
results from each study day into Excel tables. SOC and CRT are licensed from 
CANTABeclipseTM (Version 3, © 2006, Cambridge Cognition Ltd.). CPT is licensed 
through Multi-Health Systems Inc. (© 2000, 2004).  
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StarLIMS management system was used in the process of receiving, analyzing and 
storing the blood (and urine) samples (see 3.2.2). The volunteers were identified by 
tracking numbers only; no names or birthdates were registered in the StarLIMS system. 
3.3.8.2 Statistic tests
Paper III used a paired sample analysis (Wilcoxon test) when calculating the difference 
between mean performance after intake of each active drug and mean performance after 
placebo intake.  
A Pearson’s test was used for calculating differences between the shares of impaired 
observations related to the different drug concentration groups, in Paper IV. Fisher’s 
Exact test was used for calculating differences when the number of observations was low, 
in Paper IV. 
3.6 Ethical Considerations 
The data included in Paper I is coupled by each individual’s unique 11-digit identification 
number. Permission to perform the coupling was given by the Norwegian Data 
Inspectorate before the study was conducted. 
All the data used in Paper II were handled anonymously, meaning that names and 
identification numbers were replaced by a tracking number. The use of internal statistics 
was interpreted as a part of regular routine management, precluding the need to apply for 
permission before performing the study.  
The experimental study was approved by both the Regional Ethical Committee for 
Medical Research and by the Norwegian Medicines Agency. The trial was conducted in 
accordance with the Helsinki Declaration. All volunteers were given thorough 
information on the study before enrolment, and volunteers were only enrolled after 
having given a written consent. The volunteers were offered compensations of 4000 
NOK after completing all four days of the study. The volunteers were not registered by 
their personal names, but were given each a specific tracking number throughout the trial.  
- We included only male volunteers. Due to hormonal fluctuations, such as possible 
pregnancies and the common use of contraceptives, females are, in general, less 
desired as research objects. As a consequence, the evidence-based knowledge is 
less powerful for females than for males. Only male volunteers were studied to 
avoid the possible challenges of female volunteers, and because males are more 
often involved in DUI.     
- There is always a certain level of risk involved when healthy individuals receive 
drugs intended for pathologic conditions. Inducing drug- and alcohol impairment 
may be considered an even higher risk. The impression left by the volunteers, 
after participating in the study, was that the study revealed, and gave attention to, 
the negative impairing effects of zopiclone and ethanol. Only volunteers with no 
history of (self-reported) drug abuse were included in the study. 
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With all the studies, short Norwegian summaries were submitted to the press after 
publication, leading the studies to receive a certain level of attention in the Norwegian 
media. As a result, some claimed that patients suffering from insomnia were stigmatized, 
leading to an overstated fear of the effects upon zopiclone consumption, and that driving 
without taking the prescribed medicine could be even more hazardous. Our results were 
correctly referred to by the press, and it was clear that we did not compare traffic accident 
risk among insomnia patients who had taken their prescribed medicine and those who had 
not. One may argument that we, as well as any other researcher, had an ethical obligation 
to inform the public about our findings.    
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4. Summary of Results 
4.1 Aim 1: Traffic Accident Risk Related to Zopiclone Use 
Paper I revealed an increased traffic accident risk after dispensing prescriptions for all of 
the investigated hypnotics. The SIRs (95 % confidence interval (CI)) and the observed 
number of accidents are presented in Table 7. Calculations made, based upon a time 
period of 14 days after dispensing, gave slightly lower risk values for all of the hypnotics, 
as compared to 7 days of exposure. Excluding the individuals concurrently receiving 
other psychoactive drugs gave a SIR of 1.9 (1.5 - 2.4) and 2.4 (1.2 - 4.2), for zopiclone 
and nitrazepam respectively. Dispensing a zopiclone prescription after a 180-day washout 
gave a SIR of 2.1 (1.3 - 3.1). None of the other hypnotics included had a sufficient 
number of accidents to calculate incidental use. The case-crossover calculations, 
including only the drivers involved in accidents lowered the SIRs for all of the hypnotics, 
although significant results were still found for zopiclone and nitrazepam (only). The 
case-crossover results were not shown in Paper I, but included in table 7 below.  
The highest SIRs were found among the youngest age groups for all of the hypnotics.  
In general, males had higher SIRs than females, in all age groups. The largest and most 
consistent difference between males and females was observed for flunitrazepam. 
Table 7: The SIRs and the corresponding number of accidents during the observation period, for the four 
investigated hypnotic drugs. SIRs were not calculated when the number of accidents (N) was below 10  
 Zopiclone Zolpidem Nitrazepam Flunitrazepam 
 N SIR
c 95 % CI N SIR 95 % CI N SIR 95 % CI N SIR 95 % CI 
7 days of exposure
a 129 2.3 2.0-2.8 21 2.2 1.4-3.4 27 2.7 1.8-3.9 18 4.0 2.4-6.4 
14 days of exposure
a 204 2.0 1.7-2.2 38 2.1 1.5-2.9 41 2.2 1.6-3.0 25 3.1 2.0-4.6 
Concurrent users excluded
b 80 1.9 1.5-2.4 <10   11 2.4 1.2-4.2 <10   
Incidental users only
a,b 22 2.1 1.3-3.1 <10   <10   <10   
Case-crossover
a,b 129 1.4 1.2-1.7 21 1.1 0.7-1.7 27 1.7 1.1-2.5 18 1.5 0.9-2.4 
aConcurrent prescriptions for other medications were not considered 
b7 days of exposure 
cStandardized Incidence Ratio 
The mean age of the drivers involved in the car crashes exposed to zopiclone was slightly 
higher than the mean ages for the other hypnotics (46 years for zopiclone versus 40 for 
zolpidem, 39 for nitrazepam, and 38 for flunitrazepam).  
4.2 Aim 2: The Concentration-Effect Relationship between 
Zopiclone and Impairment 
Papers II, III and IV revealed positive concentration-effect relationships between blood 
zopiclone concentrations and traffic-related impairment, by using both different test 
methods and different blood zopiclone concentration levels.  
Only 9 % of the 79 individuals included in Paper II had blood zopiclone concentrations 
corresponding with a therapeutic intake (Group 1). The remaining all had higher blood 
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zopiclone concentrations than those likely following therapeutic use. In contrast, Papers 
III and IV only included moderately high blood zopiclone concentrations, few exceeding 
the values of Group 1 in Paper II.  
In paper II, 71 % of the drivers in Group 1 were considered to be impaired (19 - 32 μg/L), 
86 % in Group 2 (33 - 129 μg/L), and 97 % in Group 3 (130 μg/L or more). The 
increasing share of impaired drivers related to the increasing blood zopiclone 
concentrations was only significant between Groups 2 and 3. The lack of significance 
between Groups 1 and 2 is most likely due to the low number of drivers in Group 1.  
Paper III aimed to demonstrate mean psychomotor performance related to time after 
intake, and documented impairment at all three behavioural levels, comparing with 
placebo. The most pronounced impairment was seen for automotive behaviour. For all 
behavioural levels, impairment was greatest around one hour after intake. The mean 
blood drug concentrations observed one hour after intake were: 39 (+/-SEM 4) μg/L for 
10 mg of zopiclone, 19 (+/- SEM 2) μg/L for 5 mg of zopiclone, and 0.07 (+/-SEM 
0.003) % for BAC.  
An intake of 10 mg of zopiclone tended to show greater impairment than 5 mg of 
zopiclone for all behavioural levels, but only 4 out of the 15 test components 
demonstrated a significant performance difference between the two doses. Two of the test 
components were still able to show impairment 3.5 hours after intake of 10 mg of 
zopiclone, as compared with placebo. The mean blood zopiclone concentration at 3.5 
hours after the intake of 10 mg of zopiclone was 34 (+/-SEM 2) μg/L. Less impairment 
was found at 3.5 h after the intake of 10 mg of zopiclone (34 μg/L) compared with at one 
hour after the intake of 5 mg of zopiclone (19 μg/L), indicating some level of acute 
tolerance. 
Paper IV found a positive relationship between blood zopiclone concentrations and 
percentages of impaired observations, both for automotive behaviour and control 
behaviour. The positive relationship for blood zopiclone concentrations started at >16 
μg/L. No such relationship was found for executive planning behaviour. Furthermore, the 
curve obtained for blood zopiclone concentrations shortly (<1 hour) after intake was 
more vertical than the curve obtained later (>1 hour after intake). The positive 
relationship was significant from 1 μg/L and upwards. For blood samples collected >1 
hour after intake, slightly more impaired observations were made, in correspondence with 
higher blood drug concentrations. Observations made more than one hour after the intake 
of zopiclone showed significant impairment above 25 μg/L, indicating that there is a 
positive relationship between impairment and blood zopiclone concentrations, also with 
investigations long after intake.   
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4.3 Aim 3: Impairment, Observed at Different Blood Zopiclone 
Concentrations, Expressed as BAC 
Comparisons were made between performances at different blood zopiclone 
concentrations and different BACs, and are presented in Figure 5.  
As revealed in the figure, Papers II and IV documents that any measureable blood 
zopiclone concentration up to 20 - 30 μg/L is comparable to BACs at around 0.05 %. For 
blood zopiclone concentrations raging 30 - 40 μg/L, and up to 74 μg/L, a comparison can 
be made to BACs between 0.05 - 0.10 %.  
Only Paper II includes blood zopiclone concentrations above 74 μg/L.   
Figure 5: The relationships found between blood zopiclone concentrations and BACs in Papers II – IV 
In both Paper II and IV, zopiclone and ethanol seem to follow an overall similar response 
to the psychomotor tests. In Paper II, both drugs demonstrate a high chance of 
impairment (>70 % of the observations) among the lowest blood drug concentrations, 
gradually increasing to nearly 100 % impairment among the individuals with the highest 
blood drug concentrations. In Paper IV, results were calculated for each of the three 
behavioural levels, not showing results for each single test component. The results 
demonstrate a positive concentration-effect relationship, both for ethanol and for 
zopiclone, in relation to automotive behaviour and control behaviour, but not for 
executive planning behaviour.  
Paper III focuses on the test component results, and was able to demonstrate a different 
response pattern for ethanol compared with zopiclone. Ethanol was found to increase the 
chance for errors, while zopiclone led to a slowed response, an impaired alertness, and a 
less consistent performance.  
In Paper IV, acute tolerance was documented both for ethanol and for zopiclone. 
Zopiclone shows a clearer positive concentration-impairment relationship, also among 
the blood samples collected >1 hour after intake. The lack of a positive concentration-
effect relationship for ethanol may be explained by the low number of ethanol cases 
compared with zopiclone (double N for zopiclone). 
130μg/l 100μg/l 70μg/l 40μg/l 10μg/l 
~0.05 % 0.05 % – 0.10 % 
Blood zopiclone concentrations 
Paper II > 0.15 %  
Paper III 
Paper IV 
0.07 % 
0.03- 
0.06 %  0.06 % - 0.10 % 
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5. Discussion 
5.1 Methodological Considerations  
5.1.1 Paper I 
The entire Norwegian population aged 18 - 69 was included in the study. Use of 
nationwide registries gave a unique opportunity to study a large amount of material. 
Given that NorPD, NRAR and NCPR all were correctly updated, there were no 
information biases.  
The presented study considered only prescribed drugs, and did not register concurrent use 
of alcohol or illegal drugs. Alcohol, and to some extent illegal drugs, are considered well 
known causes of traffic accidents [32]. Patients suffering from alcohol addiction, or any 
addiction to illegal drugs, have been found to have an increased tendency to use 
benzodiazepines [37]. Concurrent use of illegal drugs and/or alcohol can therefore be a 
plausible confounder in our study.  
There was no information as to whether the drivers involved in the traffic accidents, as 
observed in this study, actually had consumed the prescribed medication before driving. 
Furthermore, if a hypnotic drug was in fact taken, there was no information on the time 
interval between the drug intake and the accident; the previous making it impossible to 
conclude on whether the hypnotic drug in question was actually present in the body at the 
time of the accident or not. The traffic accident may just as well have occurred due to a 
confounding factor related to being in a state of sleep medication requirement, i.e. any 
type of psychological imbalance, grief or recent undergone trauma. Insomnia, by itself, 
may just as well increase the risk of traffic accident involvement. The use of a prescribed, 
psychoactive drug as a confounder was, however, less likely: excluding all the 
individuals receiving other types of psychoactive drugs in addition to the hypnotic drug 
in question, did not alter the results.  
Zopiclone is often prescribed for a longer duration of treatment, beyond the 
recommended 2 - 4 weeks [35]. The share of long-term users, among those involved in 
traffic accidents, was not known. In addition, the dose and the number of tablets 
prescribed were not considered. 
There was no information on culpability, meaning that the setup did not differ between 
drivers ascribed to be the cause of the accident, and drivers through no fault of their own 
involved in an accident. Accordingly, an unknown share of the accidents included was 
obviously caused by other factors than the driver him-/herself (or his-/her prescribed 
medication).  
The increased traffic accident risk, observed among the group of young male hypnotic 
users, could indicate stronger impairing effects by the use of hypnotics in this population 
group, as compared with females and older patients suffering from insomnia. However, 
the previous statement seems unlikely, there being no proof of a stronger drug effect on 
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younger male adults. Among the elderly, an increased drug effect has been reported, 
possibly due to the pharmacokinetic changes consistent with increasing age [48]. The 
increased traffic accident risk among the younger male drivers is more likely connected 
to a problem of selection: younger male drivers are overrepresented in the group of sleep 
related car crashes [104], and a concurrent use of alcohol and/or illegal drugs is proven to 
be a strong confounder for younger males [105]. Likewise, a study on drivers, aged 65 – 
84, found that alcohol was not as likely a confounder among this group of elder drivers 
[33]. Altogether, the previous indicating a selection bias, related to a subpopulation of 
younger male drivers being at a particularly high traffic accident risk, as a result of 
younger males having personality characteristics leading to increased risk-taking 
behavior, a lower level of alertness, and/or concomitant drug use. 
It seems likely that older people would tend to drive less than younger people; mileage 
was, however, not considered in this study. A higher traffic accident risk was found for 
the younger age group, in addition to a higher risk among males compared with females. 
The same trends were repeated for all of the hypnotics studied. Given that the presented 
trends continue beyond the age of 70, and this age group being included in the study, then 
the overall SIR, for traffic accidents related to an exposure to zopiclone, would have been 
somewhat lower. The previous did not, however, have an implication for the stratified 
results related to age groups in the presented study. Because people above the age of 70 
were not included, the results should only be considered valid for the share of the 
population aged 18 - 69.  
  
5.1.2 Paper II 
The CTI is performed on individuals not necessarily representing the general Norwegian 
population of drivers. Because the study population to a large extent consist of drug 
addicts [24], this specific group of individuals may appear more “worn out” than others. 
The previous may, in turn, lead to a generally higher chance of being evaluated as 
impaired. It is widely known that zopiclone is one of the most commonly prescribed 
drugs among the elderly (and mostly among females), in Norway. Why then, does the 
study population of (mostly) apprehended drivers still consist of young male users of 
zopiclone? An explanation may be that the largest group of zopiclone users does not 
drive. Or if they do drive, they are not commonly apprehended by the police due to a 
“safer” appearance. It is likely that the police have a tendency to apprehend only the most 
impaired individuals. We have previously found a (slightly) positive relationship between 
blood amphetamine concentrations and impairment, as assessed by the (same) CTI [102]. 
The findings were followed by an academic discussion [106,107] . Seen in retrospect, the 
positive relationship, found for amphetamines, may have been revealed due to a selection 
of amphetamine-users on the descending limb of a binge abuse-period. The amphetamine 
concentrations may therefore have represented the length and intensity of the binge 
period, more than the effects of the amphetamine concentrations measured. Zopiclone 
differs greatly from amphetamines with regards to pharmacokinetics and 
pharmacodynamics, binge abuse is not reported, and one would expect an increasing 
concentration to represent greater impairment than a falling one. It is, however, of value 
41 
to acknowledge that the CTI results, in some way, probably may disclose more than the 
blood drug concentrations alone.  
Based upon assumptions of a development of acute tolerance, an over-representation of 
individuals who have consumed zopiclone shortly before time of apprehension, is to be 
expected. Given the existence of a true positive concentration-effect relationship, the 
police will apprehend more individuals with high blood zopiclone concentrations. The 
study found very few moderate blood zopiclone concentrations, which supports the 
assumption of the mentioned selection bias; all together, implying that the share of 
impaired individuals in the included material, in general, is falsely elevated. Bachs et al. 
have previously documented that among apprehended drivers, with no positive findings 
in their blood samples, only 14 % were assessed as impaired [103]. As illustrated in 
Figure 6, the selection bias would be lower among the higher blood zopiclone 
concentrations, given a true positive concentration-effect relationship. 
Figure 6: The share of apprehended individuals assessed as impaired, related to blood zopiclone 
concentrations in Paper II. The arrows indicating an assumption of true share of impaired observations 
without the selection bias 
Recommendations have been made to investigate and document the reliability and 
validity of any test applied during experimental research [108]. Even though the setup in 
Paper II is observational (non-experimental), the reliability and validity of the CTI is 
relevant, as for any test used in an experimental study design.  
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Test Reliability for the CTI 
The CTI inter-rater reliability is low due to different doctors performing the test under 
different conditions and circumstances. The test-retest reliability is not investigated.   
Test Validity for the CTI 
The validity of the Norwegian CTI is not documented. 
There are no epidemiological studies on z-hypnotics evaluating traffic accident risk in 
relation to measured blood drug concentrations. In comparison, for ethanol the evidence 
is clear: The Long Beach/Fort Lauderdale study documents an exponentially increasing 
traffic accident risk related to BACs above 0.10 - 0.15 % [3]. To visualize the possible 
validity of the CTI results, the results from the Long Beach study are plotted together 
with the CTI results, calculated as relative risk (RR), in Figure 7. The figure illustrates 
that the RR for being assessed impaired did not change much with increasing BAC 
values. In contrast, the traffic accident risk increased considerably above the level of 0.10 
%. Given that traffic accident is an applicable end-point, Figure 7 may point to a probable 
low CTI validity, and further accentuate the probable selection bias in Paper II among the 
most impaired drivers.  
Figure 7: The predictive validity for the observations of impairment made in Paper II related to traffic 
accident risk for different BACs. The dotted line shows adjusted RRs for traffic accidents for BACs 
between 0.00 - 0.25 %, as documented by Blomberg et al. [3]. The bar graphs show RRs of impaired 
observations, as found in Paper II for BAC-positive cases (and in Bachs et al. for cases without any drugs 
present [103]): RR: 6, 6, 7 and 7, respectively, for the four BAC-groups shown 
5.1.3 Paper III and IV 
Healthy male volunteers were examined in the experimental study. This population group 
is not representative for the general Norwegian driver population, or for the population 
receiving zopiclone prescriptions, but the age and the gender are comparable to the 
population of suspected DUI drivers (Paper II).  
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The use of a crossover design lowers the chance of confounders, implying that the 
reported effects, for the most part, were caused by the actual drug effects. Still, other 
study populations (e.g. patients, older drivers or females) may have reacted differently to 
the tests due to inertly different pharmacokinetic- or pharmacodynamic responses. 
Because the psychomotor findings were related to measured blood drug concentrations, 
any possible pharmacokinetic differences among individuals are considered less relevant. 
A pharmacodynamic variation among different study populations has not been uncovered 
for zopiclone.  
Three computerized tests were used to measure impairment: SOC, CRT and CPT. 
Different types of CRTs are commonly used in DUI research, while SOC and CPT are 
less often applied. Comparing results from different studies is difficult, due to different 
tests being utilized. A test battery, including tests for digital symbol substitution (DSST), 
memory, tracking and divided attention, has shown a low predictive validity for on-the-
road SDLP performance [16]. SDLP is considered a reliable test for measuring traffic 
related impairment, and the low predictive validity indicated the mentioned tests to be 
less suitable. However, to measure SDLP is not necessarily the same as measuring traffic 
accident risk. There may be other aspects of behavior, necessary for safe driving, that are 
not covered by the SDLP test. 
Test Reliability for SOC, CRT and CPT 
Computerized tests were used, making the chance of inter-rater reliability high by 
definition.  
The test-retest reliability for the computerized test components was focused in different 
ways throughout Papers III and IV. In Paper III, the mean variance of the 4 baseline test 
values, for the 16 volunteers, are revealed in the appendix. However, the tables in the 
appendix do not explain whether the variance is related to intra- or inter-individual 
variance. A kind of test-retest reliability for each volunteer is considered in Paper IV, by 
using the study’s dichotomized definition of impairment. 
Test Validity for SOC, CRT and CPT 
The test components included in the RCT, when regarded together, are meant to 
composite a picture of traffic relevant performance, based upon the three levels of 
behavior that are supposed to involve most aspects required for motor vehicle driving [8]. 
Given that the classification of the 15 test components into separate behavioural levels is 
correct, the content validity of the chosen test components, as a whole, can be considered 
quite high. 
Traffic accident risk may be regarded as the end point, and therefore the most important 
aspect, in DUI research. As previously stated, the documented positive relationship 
between traffic accident risk and BACs, as documented by Blomberg et al.[3], may be 
considered the “gold standard”, and is evidence of a true positive relationship between 
traffic-relevant impairment and BACs. The Long Beach/Fort Lauderdale study showed a 
(slightly) increasing traffic accident risk in relation to BACs between 0.00 - 0.10 [3].  In 
Figure 8, the definition of impairment, as applied in Paper IV, is used to visualize the 
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predictive validity of impairment in relation to the relative risk of a car crash. The figure 
reveals a higher predictive validity for the computerized tests, as compared with the CTI 
(showed in Figure 7).  
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     Executive planning behaviour 
Figure 8: The predictive validity for the observations made in Paper IV related to traffic accident risk for 
different BACs. The dotted lines show adjusted RRs for BACs between 0.00 - 0.10 %, as documented by 
Blomberg et al. [3]. The bar graphs show RRs of impaired observations, as found in Paper IV. Results 
representing the three behaviour levels are shown separately 
Post Hoc Power Calculation  
A post hoc power calculation on the 15 included test components was attached to Paper 
III. A brief summary of the power results are given in table 8 below. It has been claimed 
that a post hoc power analysis only restates the statistical significance of the test, and that 
it will not add anything new of value [109]. On this basis, it should be underlined that the 
post hoc power analysis did not prove that the relationship between blood drug 
concentrations and impairment was underestimated. 
Table 8: Results from the post hoc power analysis. The table shows the number of tests with sufficient 
power and, among them, the number of significant test results. Power is defined as 80 % and P < 0.05  
  Zop 10 Zop 5 EtOH 
Number of tests with  
sufficient power (N, %) 
Automotive behaviour 6 (100 %) 5 (83 %) 2 (33 %) 
Control behaviour 2 (40 %) 0 (0 %) 2 (40 %) 
Executive planning 1 (25 %) 1 (25 %) 1 (25 %) 
     
Number of significant tests  
results among the tests with 
sufficient power (N, %) 
Automotive behaviour 5 (83 %) 2 (40 %) 1 (50 %) 
Control behaviour 2 (100 %) 0 (0 %) 2 (100 %) 
Executive planning 1 (100 %) 0 (0 %) 1 (100 %) 
5.2 Aim 1: Traffic Accident Risk Related to Zopiclone Use 
Before Paper I was conducted, only one epidemiological study had documented an 
increased traffic accident risk related to zopiclone exposure [9]. Our findings of increased 
traffic accident risk, observed during the first few days after exposure to a hypnotic drug, 
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is in accordance with previous traffic accident studies on both benzodiazepines 
[10,11,29-34] and the one mentioned regarding zopiclone [9]. Furthermore, the results 
here presented are in accordance with traffic accident studies carried out after the 
presented study, on both benzodiazepines [13,68,69,110,111] and z-hypnotics [13,68,69]. 
A low number of studies have found no significant traffic accident risk among users of 
benzodiazepines [112,113]. 
For all of these studies mentioned, confounding factors may have led to an 
overestimation of the traffic accident risk in relation to the drugs in question. Barbone et 
al. followed a case-crossover setup [9], which reduces the chance of confounding factors 
related to differences between individuals because the individuals are self-matched. 
Gjerde et al. calculated the risk of being involved in a traffic accident based upon 
analytical blood drug findings (where saliva was used for the controls), including both 
alcohol and illegal drugs, in a Norwegian case-control study [13]. The study found a 
significantly increased OR for fatally injured drivers for blood samples testing positive 
for zopiclone. The increased risk persisted in cases with blood samples testing positive 
for zopiclone alone (no other drugs or alcohol being present), indicating that confounding 
effects played only a minor role. In addition, a similar pattern was found for 
benzodiazepines in general, and for diazepam, except that there was no significant 
increased traffic accident risk for either benzodiazepines alone or for diazepam alone. 
Gjerde et al. found a higher OR for benzodiazepines and diazepam than for zopiclone, 
before excluding cases with more than one detected drug. These findings may underline 
the importance of confounding effects from other psychoactive drugs, even indicating 
that alcohol and illegal drugs are stronger confounders for benzodiazepines than for 
zopiclone. An interesting observation to be made is that zopiclone alone constituted an 
increased traffic accident risk, whereas benzodiazepines and diazepam alone did not. 
Unfortunately, the N was too low to study any of the specific hypnotic drugs other than 
zopiclone. 
Another recent study aimed to exclude the use of alcohol as a confounder by requesting 
BAC analysis for all seriously injured drivers [68]. The study found a slightly increased 
risk of being responsible for the traffic accident with the use of zolpidem (OR = 1.29 (CI 
1.09-1.52), and with the use of benzodiazepine hypnotics (OR = 1.39 (CI 1.08-1.79), but 
not with the use of zopiclone. The authors explain the difference between zopiclone and 
zolpidem as related to the patterns of drug use, or by factors personally related to the 
users. Usage trends may vary between countries. In Norway, people receiving 
benzodiazepine prescriptions are generally younger and more commonly male, as 
compared with those receiving prescriptions for z-hypnotics [35].There is no clear 
difference between those receiving zopiclone prescriptions as opposed to those receiving 
zolpidem, except for the group of patients receiving zolpidem being very small.  
In addition, an epidemiological study, investigating culpability related to measured blood 
drug concentrations, found a clear, concentration-dependant relationship between alcohol 
and culpability [29]. This study also found a significant linear relationship for culpability, 
increasing with increasing blood benzodiazepine concentrations in combination with 
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other drug; likewise for benzodiazepines alone, indicating that benzodiazepines, by 
themselves, constitute an increased risk, with a positive concentration-effect relationship. 
A lower SIR was observed for users of z-hypnotics compared with that of users of 
benzodiazepines. One should, however, be cautious when comparing the results of the 
different hypnotics with each other, due to the different material. Nevertheless, it is 
interesting to observe that the case-crossover calculations reduced the SIRs dramatically, 
for all of the investigated hypnotic drugs, leaving only significant SIRs for zopiclone and 
nitrazepam. In fact, the case-crossover results did, to some degree, confirm that there may 
have been factors, in connection to the users, even more relevant, to the cause of the 
increased traffic accident risk, than the effects of the drugs prescribed. Based upon a 
possible selection bias, one may argue that the increased traffic accident risk, found 
among the group of younger male drivers, probably has evolved due to the interaction of 
several factors: personality characteristics; confounding use of alcohol and/or illegal 
drugs; confounding factors related to being in a state of sleep medication requirement and 
sleepiness in general (which may to some extent be caused by the drug itself); as well as 
the specific drug impairing effects. The decreasing traffic accident risk, found among the 
higher age-groups, as well as for females, points to a possibly different weighting of the 
presented factors with increasing age and with the female gender.  
Similar to benzodiazepines, z-hypnotics are not recommended for long-term use, and few 
studies have investigated tolerance development after longer usage. Based upon Neutel´s 
former observational studies on benzodiazepines, showing decreasing traffic accident 
risk, the longer the time had passed since collecting a benzodiazepine prescription 
[10,31], the higher a SIR was expected to be found among the incidental users, as 
compared to those exposed without a washout period. However, this was not found. In 
Paper I, similar SIRs were found after 14 days, as compared with 7 days after dispensing 
the hypnotics. The traffic accident risk after a 180-day washout was investigated for 
zopiclone only, due to the low number of cases involving zolpidem, nitrazepam or 
flunitrazepam alone. The difference lacking among the incidental users, as compared 
with those without a washout period, may be explained by a low level of tolerance 
developing to the impairing effects of zopiclone or it may be explained by a restrictive 
attitude towards driving a car related to patients receiving zopiclone rarely. Explaining 
the difference between the presented results and Neutel’s results is difficult. Different 
patterns of confounding factors in Canada, as compared with Norway, may be one 
explanation. For example, a Finnish study concluded that current illness most probably 
played a larger role in explaining traffic accidents in Finland than in other countries 
[114], thus portraying how patterns influencing traffic accident risk can vary from place 
to place. The findings above may still serve as an argument for a low development of 
tolerance to the residual effects of the investigated sleep medications, thereby explaining 
how the increased traffic accident risk may persist throughout the exposure period. Based 
upon results in Paper I, it is, however, not possible to argue for an increased traffic 
accident risk persisting beyond 14 days of exposure.   
Fatigue and a lack of sleep are both documented causes of road traffic accidents [104]. 
This documentation is based upon various methods, such as: surveys, police reports, and 
by collecting certain circumstantial evidence from the accident sites. The use of various 
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methods for documentation, makes the proportion of accidents, considered related to 
sleep deprivation, to show a great variation, ranging between 1 - 41% of all traffic 
accidents [104].  
Sleep deprivation is difficult to relate to traffic accident risk, compared with drug intake 
or drug exposure. This is because sleep deprivation is an entity considered too diffuse to 
measure. Sleep disorders may, however, serve as indicators for sleep deprivation and 
sleep deficiency. Among the sleep disorders, the respiratory sleep disorders (like sleep 
apnea) have clearly been revealed as a risk factor for traffic accident involvement 
[104,115]. Among other sleep disorders, like insomnia, the evidence is not equally clear 
cut, but this may be due to lack of research in the field [115]. One may therefore 
question, based upon the previous, whether it is safer for a patient suffering from 
insomnia to avoid, or to consume, sleep medication, as prescribed by a physician, during 
the evening before daytime driving.  
5.3 Aim 2: The Concentration-Effect Relationship between 
Zopiclone and Impairment 
Paper II documents a positive relationship between high blood zopiclone concentrations 
and impairment, as assessed by the CTI. Seeing a positive relationship, despite the low 
CTI reliability and validity, as shown in section 5.1, may indicate that the observed 
positive concentration-effect relationship represents a robust phenomenon.  
Papers III and IV documents a positive relationship, specifically for blood zopiclone 
concentrations ranging 16 – 74 μg/L, not differentiating between observations made 
shortly- or long after time of intake. Impairment was found for even lower blood 
zopiclone concentrations, during observations made less than an hour after intake. Papers 
III and IV reveal different responses at each behaviour level investigated, finding that 
automotive behaviour and control behaviour are more sensitive to the effects of 
zopiclone, in the range 0 – 74 μg/L, compared with that of executive planning. 
Given a true positive concentration-effect relationship, a higher dose will lead to greater 
effects compared with that of a low dose. The previous statement is confirmed by the 
results in Paper III, by revealing greater impairing effects after consuming 10 mg of 
zopiclone compared with the effects after 5 mg, as documented for nearly all of the test 
components. Out of the 15 test components, only 4 demonstrate a significant difference 
between the two doses. A comparatively small difference between the doses, few 
observations, and relatively high intra- and inter-individual test variability may explain 
the lack of significant results. Among the 44 RCTs, as listed in the Appendix, 7 studies 
examined more than one zopiclone dose [60,61,70,76,116-118]; all demonstrating some 
level of a greater effect or a prolonged impairment by the higher dose.  
Paper IV reports significant impairment above 16 μg/L for observations made at 
behavioural levels 1 and 2. Other studies have similarly found impairment below 20 
μg/L, specifically for the tests: DSST, FFT and RT [79] at 3 - 6 h after intake, and for 
eye-hand coordination [76] at 10 h after intake. Like Kuitunen et al., Mattila et al. also 
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measured DSST at 1.5, 4.5 and 6 h after intake. Unlike the study performed by Kuitunen, 
Mattila found no significant DSST impairment at 4.5 h after intake, even though the 
measured mean blood zopiclone concentration was 45 μg/L [81]. Driving simulator 
studies have revealed diverging results, with respect to performance related to blood 
zopiclone concentrations: Bethelon et al. found no residual effects for 30 μg/L at 9 - 10 h 
after intake of 7.5 mg of zopiclone [75], as opposed to Bocca et al., who found residual 
impairment for 24 μg/L at 10 - 11 h after intake [80]. The two studies used different 
driving simulators and varying age groups of healthy volunteers, which may account for 
some of the differences. 
Paper III documents impairment up until 3.5 h after intake. Other experimental studies 
have similarly revealed significant impairment up until 3 - 4 h after the intake of 
therapeutic sleep dosages (usually 7.5 mg of zopiclone) (63, 67, 68); while sensitive on-
the-road studies have stated traffic relevant impairment as late as 10 - 12 hours after an 
intake of 7.5 mg of zopiclone [66,84,119], see Table 3 (Section 1.4.1.5). Paper IV reveals 
a development of acute tolerance for zopiclone, with blood drug concentrations below 16 
μg/L showing a significantly higher share of impairment among observations made less 
than 1 h after intake, as compared with the observations made beyond 1 h. No other 
previous study has investigated acute tolerance for zopiclone in a similar way. One 
previous study aimed to investigate possible impairment following two different doses of 
zopiclone, and found evidence for acute tolerance: both a dosage of 3.75 mg and a dosage 
of 7.5 mg impaired the eye-hand-coordination, but the impairing effects following 7.5 mg 
of zopiclone lasted longer after time of intake (14 μg/L/10 h after intake) than that of 3.75 
mg (20 μg/L/2 h after intake) [76].  
Paper II is the first study documenting a positive concentration-effect relationship 
between blood zopiclone concentrations and CTI-results. Two former experimental 
studies, by Kuitunen et al., have tested a CTI on healthy volunteers after an intake of 7.5 
mg of zopiclone [78,79]; both studies documenting significant impairment at 2 h after 
intake, but no significant impairment at 5 h after intake. The Kuitunen studies tested only 
one dose of zopiclone, and reported a mean blood zopiclone concentration at 1.5 h of 30 
(+/- 5) μg/L and 37 (+/-10) μg/L, and at 5 h of 15 (+/-3) μg/L and 23 +/-3 μg/L. The lack 
of impairment at 5 h after intake may have been caused by the lower blood zopiclone 
concentrations and/or acute tolerance. The blood zopiclone concentrations in Paper II 
ranged between 23 - 1242 μg/L, with a median of 100 μg/L. Only 7 of the apprehended 
drivers in Paper II had a blood zopiclone concentration below 33 μg/L.  
The measured blood zopiclone concentrations in Paper III and IV were lower than 
expected. As illustrated in Figure 3 (Section 1.4.1.6), this is in accordance with some of 
the former experimental studies. It should be underlined that Figure 3 only includes drug 
intake of 7.5 mg, and that even higher doses were given. The discrepancy between the 
studies may be related to one or more of the following factors: the zopiclone 
formulations, the study populations, the analytical procedures or the blood sampling 
procedures. Only one of the studies in Figure 3 used zopiclone tablets [79], while 7 
studies used a capsular formulation, and one study failed to report the formulation [76]. 
Chromatographic methods were used to measure blood zopiclone concentrations in 6 of 
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the reported studies, and radioreceptor assay was used in one study [77] (the methods 
applied were not reported for 3 of the studies [75,76,81]). Finally, another possible 
explanation for the unexpected results may be the narrow time frames for the 
experimental setups. Because blood sampling and impairment testing both should take 
place within the short time frame of maximum impairment, most study designs will allow 
only one blood sampling within the first hour after drug intake. This sampling will 
therefore only on occasion coincide with the actual maximal blood zopiclone 
concentration. Taking several of these falsely low values and calculating the mean will 
give a misrepresenting result.
5.4 Aim 3: Impairment, Observed at Different Blood Zopiclone 
Concentrations, Expressed as BAC  
In Papers II - IV we found a positive relationship between traffic-relevant impairment, for 
blood zopiclone concentrations, comparable to that of BACs, as shown in Figure 5 
(Section 4.3). Papers III and IV both show that the effects of zopiclone and ethanol 
slightly differ with regards to the diverse test components. When the test components, at 
each behavioural level, are viewed as a whole, the effects of zopiclone and ethanol appear 
quite comparable, for each of the blood drug concentration levels tested.   
Papers III and IV documents a somewhat differing impaired behaviour after the intake of 
zopiclone compared with that of ethanol. In short, zopiclone leads to a slower response, 
while ethanol increases the error tendency. Other studies on zopiclone or benzodiazepines 
versus ethanol have similarly found the drugs responding differently [78,120].  
It is well known that impairment due to ethanol shows great inter- and intra-individual 
variation. The research, in the field of traffic-relevant impairment, is mostly based upon 
mean values for groups of individuals. One may ask if the results retrieved from the mean 
values are representative for a single individual. Especially with regards to tests with 
large inter-individual variation, mean results seem to be the least valuable. Based upon 
the same material, Paper III studies mean values, and individual values are studied in 
Paper IV. The results differ with regards to impairment at behavioral level 3, but in both 
papers the results are reported comparable for zopiclone and ethanol, at about the same 
blood drug concentration levels. 
  
Paper IV reveals a relevant amount of acute tolerance developing, both for ethanol and 
for zopiclone. Former studies that have measured blood drug concentrations, often have 
not distinguished between results obtained shortly- or long after intake, meaning that the 
documented concentrations often are a mixture of rising- and decreasing values. 
However, most studies on the effects of zopiclone have related impairment in relation to 
time after intake. This may imply that the development of acute tolerance has been 
considered in practise. For alcohol, former studies have documented acute tolerance for 
e.g. speed and reaction time, but not for alcohol-increased errors [121]. “Errors” would 
most likely correspond to behavioural level 3. We saw no trends of less acute tolerance 
for behavioural level 3 compared to levels 1 and 2 when working with Paper IV.  
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Interestingly, acute tolerance for ethanol was not found in the DRUID meta-analysis [4]. 
In our Paper IV we distinguished carefully between absorption and elimination phase for 
each of the individuals. All the 16 volunteers were in the absorption phase (for ethanol as 
well as for zopiclone) at the point-of-time for the first CPT test session. The meta-
analysis could not distinguish between absorption and eliminations that accurately. 
Schnabel et al. explained that their observations defined as being in the absorption phase 
probably also included some observations being in the elimination phase [4], which could 
explain a falsely elevated number of impaired observations in the “elimination phase” for 
the meta-analysis, and thereby explain the lack of acute tolerance in the DRUID report.  
Table 4 in Section 1.4.1.6 shows four studies relating zopiclone impairment to BAC 
values. Only the study by Kuitunen found results comparable to the results presented 
[23,78]. The measured blood zopiclone concentrations in Mattila’s study showed very 
high blood zopiclone concentrations, and were therefore not in accordance with presented 
results. Mamelak et al. [71] and Vermeeren et al. [84] found a significant impairment 
comparable to > 0.03 %, as long as 9 - 11 h after intake of 7.5 mg zopiclone, neither 
corresponding with the presented results. The divergence between the mentioned studies 
illustrates the complexity in attempting to find accurate blood drug comparisons for 
zopiclone and ethanol. 
SDLP has been documented to reveal an unambiguous relationship between deviation 
and BACs [84,119,122-125]. A deviation of 2.5 cm has been found to represent an 
impairment level of 0.05 % [122], and 5 cm has been found to represent an impairment 
level at around 0.10 % [124]. Given that zopiclone induces a similar traffic-impairing 
effect, one could expect a steadily increasing relationship between SDLP findings and 
blood drug concentration for zopiclone. A certain blood zopiclone concentration could 
therefore be compared to a certain BAC level, by obtaining the measured deviation in the 
SDLP test. The measured SDLP deviation, 9 - 10 h after an intake of 7.5 mg of 
zopiclone, has been documented at 2 - 5 cm more than for that of placebo, and is 
comparable to BACs ranging 0.05 - 0.10 % [84,119,122-125]. On the one hand, the 
previous may be regarded as evidence of comparable effects of ethanol and zopiclone. 
However, the BACs, found comparable to the residual zopiclone effects, show a 
relatively broad range of variation, indicating that it may be difficult to make precise and 
distinct comparisons between the effects of zopiclone and ethanol. Blood zopiclone 
concentrations were not measured in the mentioned SDLP studies, and may have differed 
among the individuals. It is worth to mention that the most sensitive tests, like SDLP, 
often have been used in experiments long after drug intake, and usually after a night of 
(drug-induced) sleep. The DRUID meta-analysis suggests a time-of-day effect (for 
nitrazepam), indicating that the drug-induced sleep may have caused other, and stronger, 
drug-impairing effects than the effects following daytime administration [86]. However, 
it seems more likely that the most sensitive tests have been used in experimental studies 
on residual effects, and that the less sensitive tests have been used in daytime 
experiments, investigating impairment shortly after intake. 
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Figure 9: The percentage of impaired observations from two different study designs, related to blood 
zopiclone concentrations. The bar graph shows the percentage of impaired observations found in Paper IV, 
for all observations after zopiclone intake. The solid black lines represent the percentage of apprehended 
drivers, assessed as impaired by the CTI. The negative blood drug findings are from Bachs et al. [103], and 
the lines representing positive zopiclone findings are from Paper II. 
As earlier mentioned, the DRUID meta-analysis compares a frequency of 50 % impaired 
observations to correspond with a BAC level of 0.08 %. Paper II reveals that even for the 
drivers with blood zopiclone concentrations between 19 - 32 μg/L, more than 70 % were 
assessed as impaired, and that nearly 100 % were impaired by the highest blood 
zopiclone concentrations. For ethanol, nearly 80 % were considered impaired by the 
lowest BACs (up to 0.05 %). These findings illustrate that the included material, in Paper 
II, was already selected (by the police) due to suspicious driving or due to traffic accident 
involvement. A material of randomly selected subjects, revealing the same blood drug 
concentrations as those included in Paper II, would probably have given a lower 
percentage of drivers being assessed as impaired. Figures 9 and 10 illustrate the 
divergence between the share of impaired assessments in Paper II and IV. It is interesting 
to observe that for zopiclone, as well as for ethanol, the RCT did not reach a level of 50 
% impairment, even for the highest blood drug concentrations, when all behavioral levels 
were studied together. It should, however, be underlined that more than 60 % of the 
observations were evaluated as impaired, in Paper IV, among observations performed 
shortly after intake (see Figure 4 (acute tolerance) in Paper IV), both for zopiclone and 
for ethanol. One may therefore ask if the apprehended drivers have such a high frequency 
of impairment due to a selection bias of being “worn-out” drivers, or due to a selection 
bias based upon pharmacological appearance: apprehension shortly after intake of 
zopiclone or ethanol (acute tolerance). 
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Figure 10: The percentage of impaired observations from two different study designs, related to BACs. 
The bar graph shows the percentage of impaired observations found in Paper IV, for all observations after 
ethanol intake. The solid black lines represent the percentage of apprehended drivers, assessed as impaired 
by the CTI. The negative blood drug findings are from Bachs et al. [103] and the lines representing positive 
BAC findings are from Paper II. 
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6. Conclusions  
An increased risk of traffic accident involvement was found for drivers exposed to 
zopiclone. The risk was the highest for younger male drivers.  
The increased traffic accident risk related to zopiclone exposure persisted throughout a 
case-crossover calculation, indicating a true drug-effect.  
We found a positive relationship between blood zopiclone concentrations and 
impairment, starting at 16 μg/L. The positive relationship was sustained throughout the 
higher (supra-therapeutic) concentrations.  
When studying the mean values, among the group of volunteers, impairment was not 
found beyond the first 3.5 hours after intake.  
There is evidence of an acute tolerance development, both for ethanol and zopiclone, 
resulting in a decreasing level of impairment the longer the time after intake.  
The concentration-effect relationships for zopiclone and ethanol were comparable to each 
other, within the blood drug concentration levels tested, except for that only zopiclone 
consumption gave a slow response and that ethanol consumption seemed to increase the 
chance of errors more than zopiclone.   
Both zopiclone and ethanol showed some inter-individual variation with respect to 
impaired performance after intake. The variability for zopiclone did not differ from that 
of ethanol.   
All in all, blood zopiclone concentrations seem as suited for traffic-related legal limits as 
BACs. 
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7. Suggestions for Further Research 
Possible confounding factors, related to traffic accident risk, for users of zopiclone, need 
to be further explored. The previous can be examined by repeating the study while adding 
information regarding specific blood drug concentrations on the most commonly 
impairing drugs. Such a study could answer whether the drivers involved in traffic 
accidents actually consume their prescribed medication before driving, and which blood 
drug concentrations that are present at the time of an accident. Having a large N, such a 
study may answer some questions related to the significance of age and gender. If 
culpability was to be added, a more complete picture on traffic accident risk, related to 
the sleep medication, would appear.  
More knowledge should be obtained about the extent of zopiclone abuse, e.g. the use of 
illegally obtained zopiclone and/or the use of supra-therapeutic doses. Because zopiclone 
is very commonly prescribed, it is important to reveal any knowledge on possible abuse 
potential. Such knowledge could be achieved by performing surveys. Roadside testing of 
human fluid (e.g. blood, urine or oral fluid) could (also) be performed to identify the 
extent of zopiclone abuse, in relation to traffic accident risk.
Tolerance needs also to be thoroughly investigated for zopiclone. If longtime usage 
leaves the user less impaired than single intakes, and if time after intake is a better 
predictor than blood drug concentrations, it may have large implications for interpreting 
results in forensic cases. RCTs on patients and healthy volunteers may be a suitable study 
design to explore the question of tolerance. Such a RCT on zopiclone patients is planned 
as part of an upcoming PhD study at the NIPH. In general, similar RCTs would be 
meaningful in forensic toxicology, and in clinical pharmacology, not only for zopiclone, 
but also for other common drugs of abuse (e.g. amphetamines, cannabis etc.).
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8. Epilogue: The Present Handling of DUID cases in 
Norway  
The legislation for 20 non-alcoholic drugs, in Norway, was altered to fixed blood drug 
concentration limits as of February 1st 2012 [126]. The introduction of the new system 
was made to harmonize the handling of all DUI cases, thereby decreasing the need for 
individual expert statements in cases with impairment due to non-alcoholic drugs.  
Before introducing the system of legal limits, a workgroup, appointed by the Ministry of 
Transport and Communications, proposed blood drug concentration limits for 20 non-
alcoholic drugs. For each of the 20 non-alcoholic drugs, 3 separate limits were set: a 
lower impairment limit, comparable to BAC of 0.02 %; and impairment limits for graded 
sanctions, comparable to BAC of 0.05 % and 0.12 %. Any blood drug concentration 
finding above the lower limit, in relation to operating a motor vehicle, is considered 
illegal; meaning that sanctions are required, unless the driver is able to provide evidence 
for the analytical findings being due to a prescribed treatment. Graded sanctions, such as 
conditioned imprisonment penalties, are to be sentenced if the driver’s blood drug 
concentration corresponds to BAC above 0.05 %. If a blood drug concentration is higher 
than the corresponding BAC of 0.12 %, a sentence including unconditioned 
imprisonment is set. 
As of February 1st 2012, a positive test result for any of the 20 psychoactive drugs will 
result in a request to the driver, where the driver is to produce evidence of a valid 
prescription for the drug in question. If the driver is unable to do so, then the driver will 
be sentenced by the fixed limits legislation system. If the driver is able to produce a valid 
prescription, an individual expert statement will be made.  
  
The 20 non-alcoholic drugs were chosen by the workgroup due to certain specific 
criteria: they needed to have a potential for abuse, and/or they needed to constitute an 
increased traffic accident risk. The legislative limits were proposed based upon scientific 
knowledge, with studies on healthy volunteers.  
Zopiclone is one of the 20 non-alcoholic drugs, as stated by the legislation of legal limits 
for traffic-relevant impairment. For zopiclone, the lower limit is 12 μg/L, the impairment 
limit comparable to a BAC of 0.05 % is 23 μg/L, and the impairment limit comparable to 
a BAC of 0.12 % is 58 μg/L. 
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9. Errata 
Paper II:  
- The cut-off value for the ethanol confirmation analysis is referred to in the text 
(under Methods) as 0.04 g/dL (%). The correct cut-off value should have been 
0.004 g/dL (%). 
- Analyzing Z-hypnotics were not implemented in the NIPH routine before July 
2001. In Paper II it is referred to a screening of all samples from December 2000.  
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g 
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m
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 c
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ng
es
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d 
m
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re
d 
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d 
zo
pi
cl
on
e 
co
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en
tr
at
io
ns
. 
M
or
e 
im
pa
ir
m
en
t 
fo
r 
zo
pi
cl
on
e 
an
d 
zo
lp
id
em
 
co
m
pa
re
d 
to
 
fl
un
it
ra
ze
pa
m
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B
ro
ad
hu
rs
t e
t 
al
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98
7 
B
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an
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d 
ra
nd
om
iz
ed
 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
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H
ea
lth
y 
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lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
28
.2
+
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4.
9 
ye
ar
s 
C
om
pl
ex
 
re
ac
ti
on
 ti
m
e 
Si
ng
le
 d
os
es
. 
B
ed
ti
m
e 
in
ta
ke
. T
es
ts
 
12
 h
 a
ft
er
 
in
ta
ke
 
2.
5,
 5
, 7
.5
 a
nd
 
10
 m
g 
zo
pi
cl
on
e,
 
pl
ac
eb
o 
Pl
ac
eb
o
N
o 
im
pa
ir
m
en
t 
ex
ce
pt
 1
2 
h 
af
te
r 
in
ta
ke
 o
f 
10
 m
g 
[7
0]
D
eh
li
n 
et
 
al
 1
98
3 
N
=
68
 (
75
) 
In
so
m
ni
a 
D
S
ST
, l
et
te
r 
ca
nc
el
la
ti
on
 te
st
 
R
ep
ea
te
d 
do
se
s.
 
3.
75
, 5
, 7
..5
 o
r 
10
 m
g 
B
as
el
in
e 
or
 
pl
ac
eb
o 
N
o 
re
si
du
al
 
im
pa
ir
m
en
t 
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R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
pa
ti
en
ts
, 
Ƃ 
an
d 
ƃ
68
-9
4 
ye
ar
s 
B
ed
ti
m
e 
in
ta
ke
. 
Sc
re
en
in
g 
+ 
ba
se
li
ne
 4
 
da
ys
, p
la
ce
bo
 
14
 d
ay
s,
  
ac
tiv
e 
tr
ea
tm
en
t 1
4 
da
ys
, p
la
ce
bo
 
7 
da
ys
. T
es
ts
 
pe
rf
or
m
ed
 
ev
er
y 
m
or
ni
ng
 
zo
pi
cl
on
e
fo
un
d
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]
F
ar
be
r 
et
 a
l 2
00
8 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
2 
gr
ou
ps
 o
f 
he
al
th
y 
 
Ƃ 
an
d 
ƃ
vo
lu
nt
ee
rs
:  
N
=
35
 a
du
lt
s 
(1
8-
45
 
ye
ar
s)
  
an
d 
 
N
=
36
 
el
de
rl
y 
(6
5-
80
 y
ea
rs
) 
 
D
S
ST
, S
C
T
 
(s
ym
bo
l 
co
py
in
g 
te
st
),
  
Si
ng
le
 d
os
es
.
A
du
lts
: 
B
ed
ti
m
e 
11
:0
0p
m
, d
ru
g 
in
ta
ke
 0
3:
00
a 
m
. T
es
ts
 4
 a
nd
 
6 
h 
po
st
 d
os
e.
  
E
ld
er
ly
: 
B
ed
ti
m
e 
10
:0
0p
m
 d
ru
g 
in
ta
ke
 0
2:
00
 
ar
e 
T
es
ts
 4
, 6
 
an
d 
8 
h 
po
st
 
do
se
. 
A
du
lt
s:
 7
.5
 m
g 
zo
pi
cl
on
e,
 1
0 
an
d 
20
 m
g 
in
di
pl
on
, 1
0 
m
g 
zo
lp
id
em
, 
pl
ac
eb
o 
E
ld
er
ly
: 3
,7
5 
m
g 
zo
pi
cl
on
e,
 
5 
an
d 
10
m
g 
in
di
pl
on
, 
pl
ac
eb
o 
Pl
ac
eb
o
A
du
lts
: N
o 
si
gn
 
ef
fe
ct
s 
D
S
ST
 o
r 
S
C
T
.  
E
ld
er
ly
: 
Z
op
ic
lo
ne
 
im
pa
ir
ed
 D
S
ST
 
4 
an
d 
8 
h 
af
te
r 
in
ta
ke
 
[1
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]
F
os
se
n 
et
 a
l 1
98
3 
 
A
) 
an
d 
B
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R
an
do
m
iz
ed
 
A
) 
N
=1
2 
H
ea
lth
y 
vo
lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
m
ea
n 
ag
e 
25
 y
ea
rs
 
A
) 
M
em
or
y 
(r
et
en
ti
on
, 
pa
ir
ed
 
as
so
ci
at
es
, 
vi
su
al
 m
em
or
y 
te
st
) 
R
ep
ea
te
d 
do
se
s.
 
A
) 
B
ed
tim
e 
in
ta
ke
. 
Pl
ac
eb
o 
da
y 
1-
7,
 a
ct
iv
e 
dr
ug
 
A
) 
7.
5 
m
g 
zo
pi
cl
on
e,
 2
 
m
g 
fl
un
itr
az
ep
am
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
A
) 
Pl
ac
eb
o
A
) 
Z
op
ic
lo
ne
 
im
pa
ir
ed
 
m
em
or
y 
af
te
r 
1s
t
ad
m
in
is
tr
at
io
n 
da
y.
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do
ub
le
bl
in
d 
cr
os
so
ve
r 
B
) 
N
= 
15
 
H
ea
lth
y 
vo
lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
m
ea
n 
ag
e 
23
 y
ea
rs
 
B
) 
M
em
or
y 
(d
ig
it
 le
ar
ni
ng
, 
m
em
or
y 
fo
r 
po
si
ti
on
 
(r
em
em
be
r 
w
he
re
 to
 p
la
ce
 
a 
sy
m
bo
l)
, 
vi
su
al
 m
em
or
y)
 
da
y 
8-
14
, 
pl
ac
eb
o 
da
y 
15
-2
1,
 a
ct
iv
e 
dr
ug
 d
ay
 2
2-
28
. T
es
ts
 1
1 
h 
af
te
r 
in
ta
ke
 
da
ys
 1
, 7
, 8
, 
14
, 1
5,
 2
1,
 2
2 
an
d 
28
 
B
) 
In
ta
ke
 a
t 
9:
00
pm
. 4
x3
 
da
ys
 o
f 
ac
ti
ve
 
dr
ug
s 
se
pa
ra
te
d 
by
 
pl
ac
eb
o 
w
as
ho
ut
s.
 
T
es
ts
 1
0 
h 
af
te
r 
in
ta
ke
 
da
y 
1 
an
d 
3 
in
 
ea
ch
 p
er
io
d.
 
B
) 
7.
5 
m
g 
zo
pi
cl
on
e,
 5
 
m
g 
ni
tr
az
ep
am
, 
2 
m
g 
fl
un
itr
az
ep
am
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
B
) 
Pl
ac
eb
o 
B
) 
N
o 
re
si
du
al
 
im
pa
ir
m
en
t 
fo
un
d 
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]
G
ri
ff
it
hs
 e
t a
l 
19
86
 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
10
 
H
ea
lth
y 
ƃ
vo
lu
nt
ee
rs
 
20
-2
2 
ye
ar
s 
S
tr
oo
p 
te
st
 (
e.
g.
 
“g
re
en
” 
pr
in
te
d 
in
 r
ed
),
 S
er
ia
l 
R
T
, l
et
te
r 
re
ca
ll
, l
og
ic
al
 
re
as
on
in
g,
 
m
em
or
y 
Si
ng
le
 d
os
es
 
In
ta
ke
 9
:3
0a
m
. 
T
es
ts
 a
t 
ba
se
li
ne
 a
nd
 1
, 
4 
an
d 
10
 h
 
af
te
r 
in
ta
ke
. 
7.
5 
m
g 
zo
pi
cl
on
e,
 1
5 
m
g 
fl
ur
az
ep
am
, 
1 
m
g 
lo
rm
et
az
ep
am
, 
0.
25
 m
g 
tr
ia
zo
la
m
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 S
R
T
 a
t 
1 
h 
(e
rr
or
s 
an
d 
la
te
nc
y)
, a
nd
 
in
cr
ea
se
d 
m
ea
n 
ti
m
e 
to
 
co
m
pl
et
e 
lo
gi
ca
l 
re
as
on
in
g 
un
ti
l 
4h
.  
[1
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]
G
ro
bl
er
 
et
 a
l 2
00
0 
D
ou
bl
e 
bl
in
d 
N
=
12
 
H
ea
lth
y 
at
hl
et
es
  
E
ye
-h
an
d 
co
or
di
na
ti
on
, 
sp
ri
nt
-t
es
t, 
Si
ng
le
 d
os
es
. 
In
ta
ke
 a
t 
10
:0
0p
m
.  
7.
5 
m
g
Z
op
ic
lo
ne
, 2
 
m
g 
lo
pr
az
ol
am
, 
Pl
ac
eb
o
D
id
 n
ot
 im
pa
ir
  
an
y 
of
 th
e 
te
st
s 
10
 h
 a
ft
er
 in
ta
ke
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cr
os
so
ve
r
Ƃ 
an
d 
ƃ
m
ea
n 
ag
e 
22
.8
 (
+
/-
 
2.
5)
 
gr
ad
ed
 
tr
ea
dm
il
l 
T
es
ts
 
pe
rf
or
m
ed
 
ne
xt
 m
or
ni
ng
, 
10
 h
 a
ft
er
 
in
ta
ke
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ac
eb
o 
(c
ap
su
le
s)
 
(s
am
e 
fo
r 
lo
pr
az
ol
am
) 
[1
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H
ar
ri
so
n 
et
 a
l 
19
85
 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
 
cr
os
so
ve
r 
S
am
e 
st
ud
y 
as
 
S
ub
ha
n 
et
 a
l 
19
84
 [
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5]
 
N
=
9 
(1
0)
 
H
ea
lth
y 
Ƃ
vo
lu
nt
ee
rs
 
24
-4
0 
ye
ar
s 
C
F
F,
 C
R
T
, 
S
te
rn
be
rg
 te
st
 
(i
nf
or
m
at
io
n 
pr
oc
es
si
ng
),
 
tr
ac
ki
ng
, m
ea
n 
br
ak
e 
ti
m
e 
(s
im
ul
at
ed
 c
ar
 
dr
iv
in
g)
 
Si
ng
le
 d
os
es
. 
E
ve
ni
ng
 
in
ta
ke
. T
es
ts
 
be
fo
re
 s
le
ep
 
(b
ef
or
e 
dr
ug
 
in
ta
ke
 a
nd
 
1.
5h
 a
ft
er
 
in
ta
ke
),
 a
nd
 
af
te
r 
sl
ee
p 
(1
0 
h 
af
te
r 
in
ta
ke
) 
7.
5 
m
g 
zo
pi
cl
on
e,
 1
 
m
g 
lo
rm
et
az
ep
am
, 
1 
m
g 
fl
un
itr
az
ep
am
, 
0.
25
 m
g 
tr
ia
zo
la
m
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 o
nl
y 
re
ac
ti
on
 ti
m
e 
on
 
th
e 
in
fo
rm
at
io
n 
pr
oc
es
si
ng
 ta
sk
 
1 
h 
af
te
r 
in
ta
ke
. 
N
o 
zo
pi
cl
on
e 
re
si
du
al
 e
ff
ec
ts
 
10
 h
 a
ft
er
 in
ta
ke
 
O
nl
y 
fl
un
it
ra
ze
pa
m
 h
ad
 
si
gn
 r
es
id
ua
l 
ef
fe
ct
s 
10
 h
 a
ft
er
 
in
ta
ke
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]
H
em
m
et
er
 e
t 
al
 2
00
0 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
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H
ea
lth
y 
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lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
(6
0-
70
 
ye
ar
s)
 
C
F
F,
 C
R
T
, 
le
tt
er
 
ca
nc
el
la
ti
on
 
te
st
, m
em
or
y 
(d
ig
it
 s
pa
n 
/ 
w
or
ki
ng
 
m
em
or
y 
an
d 
re
ca
ll
 te
st
 / 
lo
ng
 
te
rm
 m
em
or
y)
 
Si
ng
le
 d
os
es
. 
D
ru
g 
in
ta
ke
 a
t 
9:
30
pm
, l
ig
ht
s 
ou
t a
t 
10
:0
0p
m
. 
T
es
ts
 b
ef
or
e 
in
ta
ke
 (
8p
m
),
 
du
ri
ng
 s
le
ep
 
(2
am
) 
an
d 
af
te
r 
sl
ee
p 
(7
am
 a
nd
 
9a
m
) 
7.
5 
m
g 
zo
pi
cl
on
e,
 2
0 
m
g 
te
m
az
ep
am
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
B
as
el
in
e
Z
op
ic
lo
ne
 
im
pa
ir
ed
 C
F
F,
 
C
R
T
 a
nd
 s
im
pl
e 
at
te
nt
io
n 
as
 d
id
 
pl
ac
eb
o.
 F
or
 
w
or
d 
re
ca
ll
 o
nl
y 
zo
pi
cl
on
e 
im
pa
ir
ed
 4
.5
 h
 
af
te
r 
in
ta
ke
 
(p
la
ce
bo
 N
S)
 
[1
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]
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aw
a 
et
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00
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R
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m
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ub
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 b
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cr
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r 
N
=
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H
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lth
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ƃ
vo
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ye
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s 
M
em
or
y 
te
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s 
(w
or
d 
re
ca
ll,
 
pa
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ag
e 
re
ca
ll 
an
d 
S
te
rn
be
rg
 
te
st
) 
Si
ng
le
 d
os
e.
 
D
ru
g 
in
ta
ke
 
8:
00
pm
, 
be
dt
im
e 
11
:0
0p
m
, 
fo
rc
ed
 
7.
5 
m
g 
zo
pi
cl
on
e,
 1
0 
m
g 
zo
lp
id
em
 , 
pl
ac
eb
o 
(c
ol
ou
re
d 
ta
bl
et
s)
 
Pl
ac
eb
o
N
o 
re
si
du
al
 
ef
fe
ct
s 
on
 
m
em
or
y 
12
.5
 h
 
af
te
r 
in
ta
ke
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. T
es
ts
 
pe
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m
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.5
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d 
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.5
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r 
in
ta
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K
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n 
et
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19
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R
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m
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ub
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 b
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d 
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os
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N
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H
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an
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ƃ
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ye
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s 
D
ri
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ng
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m
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at
or
 
(t
ra
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in
g,
 
er
ro
rs
, R
T
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D
iv
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ed
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te
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n,
 
D
S
ST
, M
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do
x 
w
in
g 
te
st
, 
F
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er
 f
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n,
 
B
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y 
sw
ay
,  
C
T
I 
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 d
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.
T
es
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m
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m
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 b
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in
e,
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an
d 
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ke
. 
C
T
I 
2 
an
d 
5 
h 
af
te
r 
in
ta
ke
 
7.
5 
m
g 
zo
pi
cl
on
e,
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00
 
m
g 
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ep
in
e;
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e 
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 in
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m
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na
ti
on
, 
pl
ac
eb
o 
(t
ab
le
ts
) 
 
B
as
el
in
e 
(p
la
ce
bo
 f
or
 
C
T
I)
 
Z
op
ic
lo
ne
 
im
pa
ir
ed
 
tr
ac
ki
ng
 e
rr
or
s 
1.
5 
h 
af
te
r 
in
ta
ke
 (
30
+
/-
5 
μ
g/
l)
, C
T
I 
2 
h 
af
te
r 
in
ta
ke
, 
F
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 a
nd
 b
od
y 
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ay
 u
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il
 3
 h
 
af
te
r 
in
ta
ke
 
(1
8+
/-
3 
μ
g/
l)
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R
T
 u
nt
il 
4.
5 
h 
af
te
r 
in
ta
ke
 (
15
 
+
/-
3 
μ
g/
l)
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D
S
ST
 u
nt
il 
6 
h 
af
te
r 
in
ta
ke
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+
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μ
g/
l)
. 
N
o 
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ea
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fe
ct
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on
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K
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N
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H
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an
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ƃ
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ye
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s 
D
S
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, S
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l 
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in
g,
 C
F
F,
 
M
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do
x 
w
in
g,
 
B
od
y 
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e,
 
D
iv
id
ed
 
at
te
nt
io
n,
  
Si
m
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at
or
 (
5 
m
in
 tr
ac
ki
ng
 
an
d 
er
ro
rs
),
  
C
T
I 
 
Si
ng
le
 d
os
es
.
T
es
ts
 
pe
rf
or
m
ed
 +
 
bl
oo
d 
sa
m
pl
ed
 
at
 b
as
el
in
e 
an
d 
1.
5,
 3
, 4
.5
, 6
 
an
d 
8 
h 
af
te
r 
in
ta
ke
. 
7.
5 
m
g 
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pi
cl
on
e,
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.2
5 
m
g 
tr
ia
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la
m
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
0.
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et
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no
l, 
pl
ac
eb
o 
(d
ri
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).
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ee
p 
m
ed
ic
in
es
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ac
eb
o 
(o
r 
ba
se
li
ne
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Z
op
ic
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ne
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ir
ed
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 p
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T
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μ
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D
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T
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m
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l 
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r 
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C
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 m
os
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y 
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T
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s.
 
B
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m
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so
m
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R
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m
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ƃ
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ye
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s 
R
T
, t
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ng
 
ra
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, D
S
ST
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S
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bo
l 
co
py
in
g 
te
st
  
Si
ng
le
 d
os
es
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B
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ti
m
e 
in
ta
ke
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es
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pe
rf
or
m
ed
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0 
an
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 h
 a
ft
er
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t 
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2.
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 5
, 7
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 a
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 m
g 
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e,
 
pl
ac
eb
o 
(t
ab
le
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Pl
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eb
o
7.
5 
m
g 
zo
pi
cl
on
e 
im
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ir
ed
 D
S
ST
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 1
3 
h 
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te
r 
in
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 a
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m
bo
l c
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h 
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te
r 
in
ta
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 m
g 
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pi
cl
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e 
im
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ed
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g 
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r 
in
ta
ke
 a
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D
S
ST
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bo
l 
co
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in
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d 
R
T
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 m
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m
pa
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T
 
10
 h
 a
ft
er
 in
ta
ke
. 
[1
19
]
L
eu
fk
en
s 
et
 a
l 
20
09
 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
18
H
ea
lth
y 
vo
lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
55
-7
5 
ye
ar
s 
S
ta
nd
ar
di
ze
d 
hi
gh
w
ay
 
dr
iv
in
g 
te
st
 
(S
D
L
P,
 S
D
S)
 
an
d 
 la
bo
ra
to
ry
 
te
st
s 
(C
T
T
, 
D
iv
id
ed
 
at
te
nt
io
n,
 S
to
p 
si
gn
al
, w
or
d 
le
ar
ni
ng
, b
od
y 
sw
ay
) 
Si
ng
le
 d
os
es
.
B
ed
ti
m
e 
in
ta
ke
 
aw
ak
en
ed
 8
 h
 
af
te
r 
in
ta
ke
. 
D
ri
vi
ng
 te
st
 
10
-1
1 
h 
af
te
r 
in
ta
ke
 a
nd
 
la
bo
ra
to
ry
 
te
st
s 
ca
 1
2 
h 
af
te
r 
in
ta
ke
 
7.
5 
m
g 
zo
pi
cl
on
e,
 2
0 
m
g 
te
m
az
ep
am
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 S
D
L
P
 
10
h 
af
te
r 
in
ta
ke
, 
bo
dy
 s
w
ay
 9
 h
 
af
te
r 
in
ta
ke
 a
nd
 
im
pa
ir
ed
 S
to
p 
si
gn
al
 ta
sk
 
(i
nh
ib
it
or
y 
co
nt
ro
l)
, 
de
la
ye
d 
w
or
d 
re
ca
ll
, i
m
pa
ir
ed
 
w
or
d 
re
co
gn
it
io
n 
an
d 
de
la
ye
d 
re
ac
tio
n 
ti
m
e 
12
 h
 a
ft
er
 
in
ta
ke
 
A
 s
im
il
ar
 S
D
L
P
 
im
pa
ir
m
en
t  
le
ve
l 
(0
.5
 c
m
 la
rg
er
) 
ha
s 
pr
ev
io
us
ly
 b
ee
n 
fo
un
d 
fo
r 
B
A
C
s 
of
 
0.
05
%
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[1
22
]
L
eu
fk
en
s 
et
 a
l 
20
09
 D
ou
bl
e 
bl
in
d 
cr
os
so
ve
r 
N
=
28
 (
25
)
Ƃ 
an
d 
ƃ
H
ea
lth
y 
vo
lu
nt
ee
rs
 
22
-4
4 
ye
ar
s 
S
ta
nd
ar
di
ze
d 
hi
gh
w
ay
 
dr
iv
in
g 
te
st
 
(S
D
L
P)
, a
nd
 
la
bo
ra
to
ry
 te
st
s 
(C
T
T
, D
iv
id
ed
 
at
te
nt
io
n,
 
D
S
ST
, w
or
d 
le
ar
ni
ng
 te
st
, 
bo
dy
 s
w
ay
) 
Si
ng
le
 d
os
es
. 
Z
op
ic
lo
ne
 
in
ta
ke
 a
t 2
3:
00
 
L
ab
 te
st
s 
07
:3
0-
08
:1
5 
dr
iv
in
g 
09
:0
0-
10
:0
0 
7.
5 
m
g 
zo
pi
cl
on
e,
 1
5 
m
g 
ga
bo
xa
do
l, 
10
 m
g 
zo
lp
id
em
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 
dr
iv
in
g 
10
-1
1 
h 
af
te
r 
in
ta
ke
. 
Z
op
ic
lo
ne
 
im
pa
ir
ed
 D
S
ST
, 
w
or
d 
le
ar
ni
ng
 
an
d 
bo
dy
 s
w
ay
 
8.
5-
9 
h 
af
te
r 
in
ta
ke
 
A
 s
im
il
ar
 S
D
L
P
 
im
pa
ir
m
en
t  
le
ve
l 
ha
s 
pr
ev
io
us
ly
 
be
en
 f
ou
nd
 f
or
 
B
A
C
s 
of
 0
.0
5%
 
[7
1]
M
am
el
ak
 
et
 a
l 1
98
7 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
N
=
30
 
ch
ro
ni
c 
in
so
m
ni
a 
pa
ti
en
ts
  
Ƃ 
an
d 
ƃ
32
-6
0 
ye
ar
s 
D
S
ST
, 
im
m
ed
ia
te
 a
nd
 
de
la
ye
d 
m
em
or
y,
 
ba
ck
w
ar
d 
m
as
ki
ng
, 
ba
la
nc
e,
 c
ri
tic
al
 
tr
ac
ki
ng
,  
M
ul
ti
pl
e 
do
se
s.
 S
le
ep
 
m
ed
ic
in
e 
gi
ve
n 
at
 1
1:
00
 
pm
 1
2 
co
ns
ec
ut
iv
e 
da
ys
. T
es
ts
 
pe
rf
or
m
ed
 
fi
rs
t a
nd
 la
st
 
da
ys
 o
f 
tr
ea
tm
en
t, 
11
, 
13
.5
 a
nd
 1
5 
h 
af
te
r 
in
ta
ke
. 
(A
lc
oh
ol
 
in
ta
ke
 a
t 
da
yt
im
e,
 a
ft
er
 
sl
ee
pi
ng
) 
7.
5 
m
g 
zo
pi
cl
on
e,
  3
0 
m
g 
fl
ur
az
ep
am
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
(0
,5
g/
kg
 
et
ha
no
l)
 
Sl
ee
p 
m
ed
ic
in
es
 
gi
ve
n 
al
on
e 
or
 
in
 c
om
bi
na
ti
on
 
w
it
h 
al
co
ho
l  
B
as
el
in
e 
an
d 
pl
ac
eb
o 
N
o 
re
si
du
al
 
ef
fe
ct
s 
fo
r 
zo
pi
cl
on
e 
[1
38
]
M
at
ti
la
 
et
 a
l 1
99
2 
D
ou
bl
e 
bl
in
d 
 
N
=
18
 
St
ud
en
ts
 
D
S
ST
, F
FT
, 
M
ad
do
x 
w
in
g 
an
d 
dr
iv
in
g 
si
m
ul
at
or
 (
2 
m
in
 tr
ac
ki
ng
 
te
st
) 
Si
ng
le
 d
os
es
. 
T
es
ts
 
pe
rf
or
m
ed
 0
, 
0.
5 
an
d 
1.
5 
h 
af
te
r 
in
ta
ke
 
7.
5
m
g 
zo
pi
cl
on
e,
 
pl
ac
eb
o 
(u
nc
oa
te
d 
ta
bl
et
s)
: w
it
h 
or
 
w
it
ho
ut
 3
00
 m
g 
ca
ff
ei
ne
 / 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 D
S
ST
 
an
d 
M
ad
do
x 
w
in
g,
 u
nt
il 
90
 
m
in
ut
es
 a
ft
er
 
in
ta
ke
 a
nd
 F
FT
 
un
til
 3
0 
m
in
ut
es
 
O
nl
y 
m
in
or
 
di
ff
er
en
ce
s 
be
tw
ee
n 
zo
pi
cl
on
e 
al
on
e 
an
d 
zo
pi
cl
on
e+
ca
ff
ei
ne
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de
ca
ff
ei
na
te
d 
co
ff
ee
 a
s 
pl
ac
eb
o 
af
te
r 
in
ta
ke
 
[8
1]
M
at
ti
la
 
et
 a
l 1
99
4 
D
ou
bl
e 
bl
in
d 
cr
os
so
ve
r 
N
=
12
 
H
ea
lth
y 
vo
lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
19
-3
2 
ye
ar
s 
“G
lo
ba
l 
pe
rf
oa
m
nc
e”
 
(D
S
ST
, 
tr
ac
ki
ng
 e
rr
or
s 
an
d 
R
T
),
 b
od
y 
ba
la
nc
e,
 
si
m
ul
at
ed
 
dr
iv
in
g 
m
em
or
y 
(r
ec
al
l)
  
Si
ng
le
 d
os
es
. 
D
ay
ti
m
e 
in
ta
ke
.  
 
T
es
ts
 
pe
rf
or
m
ed
 0
, 
1.
5,
 3
.5
 a
nd
 6
 
h 
af
te
r 
in
ta
ke
. 
B
lo
od
 
sa
m
pl
in
g 
af
te
r 
ea
ch
 te
st
 
se
ss
io
n.
 
7.
5 
m
g 
zo
pi
cl
on
e,
 0
.4
 
m
g 
su
ri
cl
on
e,
 
50
 m
g 
ch
lo
rp
ro
m
az
in
e 
pl
ac
eb
o 
(c
ap
su
le
s)
 
Pl
ac
eb
o 
Z
op
ic
lo
ne
 
im
pa
ir
ed
 
“g
lo
ba
l 
pe
rf
or
m
an
ce
” 
at
 
1.
5 
h 
(5
2 
μ
g/
l)
 
an
d 
D
S
ST
 u
nt
il 
3.
5 
h 
(4
5 
μ
g/
l)
.  
[7
7]
M
at
ti
la
 
et
 a
l 1
99
7 
R
an
do
m
iz
ed
, 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
12
 
H
ea
lth
y 
vo
lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
19
-3
0 
ye
ar
s 
Y
es
/N
o 
di
gi
t 
sy
m
bo
l 
su
bs
tit
ut
io
n 
te
st
 
(Y
N
D
ST
),
 
sy
m
bo
l d
ig
it
 
su
bs
tit
ut
io
n 
te
st
 
(S
D
ST
),
 d
ig
it
-
di
gi
t c
op
yi
ng
 
te
st
 (
D
D
C
T
) 
Si
ng
le
 d
os
es
. 
T
es
ts
 
pe
rf
or
m
ed
 a
t 
ba
se
li
ne
, 1
, 
3.
5 
an
d 
5 
h 
af
te
r 
in
ta
ke
. 
B
lo
od
 
sa
m
pl
in
g 
af
te
r 
ea
ch
 te
st
 
se
ss
io
n,
 
ex
pr
es
se
d 
as
 
di
az
ep
am
 
eq
ui
va
le
nt
s.
 
7.
5 
m
g 
zo
pi
cl
on
e,
  
15
 m
g 
zo
lp
id
em
, 1
5 
m
g 
di
az
ep
am
, 
30
 m
g 
ox
az
ep
am
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
0.
65
+ 
0.
35
 g
/k
g 
et
ha
no
l, 
pl
ac
eb
o 
(d
ri
nk
) 
Pl
ac
eb
o:
 
D
el
ta
 
pe
rf
or
m
an
ce
 
(t
re
at
m
en
t –
ba
se
li
ne
) 
fo
r 
ac
tiv
e 
dr
ug
 
co
m
pa
re
d 
to
 
de
lt
a 
pe
rf
or
m
an
ce
 
fo
r 
pl
ac
eb
o 
Z
op
ic
lo
ne
 
im
pa
ir
ed
 
Y
N
D
ST
 a
nd
 
S
D
ST
 1
 a
nd
 3
.5
 
h 
af
te
r 
in
ta
ke
. 
N
o 
im
pa
ir
m
en
t 
5 
h 
af
te
r 
in
ta
ke
  
C
om
pa
ra
bl
e 
re
su
lt
s 
fo
r 
zo
pi
cl
on
e 
an
d 
et
ha
no
l f
or
 a
ll 
ti
m
e 
po
in
ts
, i
.e
. 0
.0
82
 
%
 c
or
re
sp
on
de
d 
to
 
1 
h 
af
te
r 
in
ta
ke
, 
0.
08
8 
%
 
co
rr
es
po
nd
ed
 to
 
3.
5 
h 
af
te
r 
in
ta
ke
 
an
d 
0.
06
0 
%
 
co
rr
es
po
nd
ed
 to
 5
 
h 
af
te
r 
in
ta
ke
 
[8
5]
M
at
ti
la
 
et
 a
l 1
99
8 
D
ou
bl
e 
bl
in
d 
cr
os
so
ve
r 
(e
th
an
ol
 
N
=
12
 
H
ea
lth
y 
vo
lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
21
-2
8 
ye
ar
s 
D
S
ST
, D
ri
vi
ng
 
si
m
ul
at
or
 
(t
ra
ck
in
g,
 R
T
),
 
bo
dy
 b
al
an
ce
, 
C
F
F,
 m
em
or
y 
(w
or
d 
re
ca
ll 
Si
ng
le
 d
os
es
.  
T
es
ts
 
pe
rf
or
m
ed
 a
t 
ba
se
li
ne
, 1
, 
3.
5 
an
d 
5 
h 
af
te
r 
in
ta
ke
. 
7.
5 
m
g 
zo
pi
cl
on
e,
  
15
 m
g 
zo
lp
id
em
, 1
5 
m
g 
di
az
ep
am
, 
30
 m
g 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 D
S
ST
, 
tr
ac
ki
ng
 e
rr
or
; 
R
T
 a
nd
 b
od
y 
sw
ay
 1
 h
 a
ft
er
 
in
ta
ke
 a
nd
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re
su
lt
s 
fr
om
 
M
at
ti
la
 e
t a
l 
19
97
) 
te
st
)
M
ea
su
re
d 
bl
oo
d 
dr
ug
 
co
nc
en
tr
at
io
ns
 
an
d 
B
A
C
s.
 
ox
az
ep
am
 , 
pl
ac
eb
o 
(c
ap
su
le
s)
 
0.
65
+ 
0.
35
 g
/k
g 
et
ha
no
l, 
re
sp
. 
pl
ac
eb
o 
D
S
ST
 3
.5
 h
 
af
te
r 
in
ta
ke
. 
[1
39
]
M
es
ka
li 
et
 a
l 2
00
9 
B
al
an
ce
d 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
16
 
H
ea
lth
y 
vo
lu
nt
ee
rs
 
Ƃ 
an
d 
ƃ
55
-6
5 
ye
ar
s 
D
ri
vi
ng
 
si
m
ul
at
or
: (
7 
m
in
 u
rb
an
 
dr
iv
in
g 
pe
rf
or
m
an
ce
 5
0 
km
/h
, 5
 
ac
ci
de
nt
s 
sc
en
ar
io
s)
 
Si
ng
le
 d
os
es
. 
In
ta
ke
 1
1:
00
 
pm
. T
es
t a
ft
er
 
sl
ee
p,
 1
0 
h 
af
te
r 
in
ta
ke
. 
7.
5 
m
g 
zo
pi
cl
on
e,
 1
 
m
g 
fl
un
itr
az
ep
am
, 
10
 m
g 
zo
lp
id
em
, 
pl
ac
eb
o 
(c
ap
su
le
s)
 
Pl
ac
eb
o
N
o 
si
gn
if
ic
an
t 
im
pa
ir
m
en
t 1
0 
h 
af
te
r 
in
ta
ke
 
(a
ls
o 
no
t f
or
 
fl
un
it
ra
ze
pa
m
 
or
 z
ol
pi
de
m
) 
[1
25
]
M
et
s 
et
 
al
 2
01
1 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
30
 
H
ea
lth
y 
vo
lu
nt
ee
rs
  
Ƃ 
an
d 
ƃ
m
ea
n 
ag
e 
25
.9
 (
SD
 
6.
5)
 
S
ta
nd
ar
di
ze
d 
hi
gh
w
ay
 
dr
iv
in
g 
pe
rf
or
m
an
ce
 
(S
D
L
P,
 S
D
S)
, 
ba
la
nc
e 
te
st
 
(b
od
y 
sw
ay
),
 
P
sy
ch
om
et
ri
c 
te
st
s 
(W
or
d 
le
ar
ni
ng
 te
st
, 
S
te
rn
be
rg
 te
st
, 
T
ra
ck
in
g 
te
st
 
an
d 
D
iv
id
ed
 
at
te
nt
io
n)
  
Si
ng
le
 d
os
es
.
B
al
an
ce
 te
st
 a
t 
ba
se
li
ne
. 
In
ta
ke
 3
0 
m
in
 
be
fo
re
 li
gh
ts
 
ou
t. 
 B
al
an
ce
 
te
st
 1
.5
 h
 a
ft
er
 
in
ta
ke
, 
w
ak
eu
p 
7.
5 
h 
af
te
r 
in
ta
ke
. 
L
ab
 te
st
s 
an
d 
dr
iv
in
g 
te
st
s 
st
ar
te
d 
8.
5 
or
 
10
 h
 a
ft
er
 
in
ta
ke
  
7.
5m
g 
zo
pi
cl
on
e,
 8
 
m
g 
ra
m
el
to
n,
 
pl
ac
eb
o 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 te
st
s 
8.
5-
10
 h
 a
ft
er
 
in
ta
ke
: S
D
L
P,
 
re
ac
ti
on
 ti
m
e,
 
D
S
ST
, w
or
d 
de
la
ye
d 
re
ca
ll 
tr
ac
ki
ng
. 
Z
op
ic
lo
ne
 
im
pa
ir
ed
 
ba
la
nc
e 
at
 1
.5
 h
 
af
te
r 
in
ta
ke
. 
A
 s
im
il
ar
 S
D
L
P
 
im
pa
ir
m
en
t  
le
ve
l 
ha
s 
pr
ev
io
us
ly
 
be
en
 f
ou
nd
 f
or
 
B
A
C
s 
of
 0
.0
5 
%
 
[1
16
]
M
iz
uk
i 
et
 a
l 1
98
3 
D
ou
bl
e 
bl
in
d 
cr
os
so
ve
r 
N
=
16
  ƃ
H
ea
lth
y 
un
iv
er
si
ty
 
st
ud
en
ts
  
A
ri
th
m
et
ic
  
ad
di
ti
on
 te
st
  
Si
ng
le
 d
os
es
. 
T
es
ts
 
pe
rf
or
m
ed
 a
t 
ba
se
li
ne
 a
nd
 1
 
5 
an
d 
10
 m
g 
 
zo
pi
cl
on
e,
 5
 
m
g 
di
az
ep
am
, 
pl
ac
eb
o 
Pl
ac
eb
o
Z
op
ic
lo
ne
 
im
pa
ir
ed
 th
e 
te
st
 r
es
ul
ts
 in
 a
 
do
se
-r
el
at
ed
 
Z
op
ic
lo
ne
 5
 m
g 
im
pa
ir
ed
 m
or
e 
th
an
 5
 m
g 
di
az
ep
am
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20
-2
5 
ye
ar
s
h 
af
te
r 
in
ta
ke
(t
ab
le
ts
)
m
an
ne
r 
1 
h 
af
te
r 
in
ta
ke
. 
[1
40
]
M
oo
n 
et
 a
l 1
99
0 
R
an
do
m
iz
ed
 
do
ub
le
 b
lin
d 
cr
os
so
ve
r 
N
=
12
 ƃ
sh
if
tw
or
ke
rs
 
18
-3
5 
ye
ar
s 
C
F
F,
 C
R
T
, 
D
S
ST
 
M
ul
ti
pl
e 
do
se
s.
 
T
re
at
m
en
t 4
 
co
ns
ec
ut
iv
e 
da
ys
 a
t 
be
dt
im
e.
  
T
es
ts
 
pe
rf
or
m
ed
 
be
gi
nn
in
g 
an
d 
en
d 
of
 e
ve
ry
 
sh
if
t. 
7.
5 
m
g 
zo
pi
cl
on
e,
 
pl
ac
eb
o 
Pl
ac
eb
o
N
o 
im
pa
ir
in
g 
ef
fe
ct
s 
fr
om
 
zo
pi
cl
on
e 
 
P
os
iti
ve
 le
ar
ni
ng
 
ef
fe
ct
 f
ro
m
 f
ir
st
 to
 
se
co
nd
 te
st
 c
yc
le
 
(S
tu
dy
 p
er
fo
rm
ed
 
by
 R
hõ
ne
-P
ou
le
nc
 
lt
d)
 
[1
18
]
N
ic
ho
ls
on
 e
t 
al
 1
98
3 
D
ou
bl
e 
bl
in
d 
cr
os
so
ve
r 
N
=
6 
H
ea
lth
y 
ƃ
vo
lu
nt
ee
rs
 
21
-3
3 
ye
ar
s 
D
S
ST
, s
ym
bo
l 
co
py
 te
st
 
Si
ng
le
 d
os
es
. 
B
ed
ti
m
e 
in
ta
ke
. T
es
ts
 
pe
rf
or
m
ed
 9
 h
 
af
te
r 
in
ta
ke
. 
2.
5,
 5
, 7
.5
 a
nd
 
10
 m
g 
zo
pi
cl
on
e,
 
pl
ac
eb
o 
(c
ap
su
le
s)
 
Pl
ac
eb
o
7.
5 
an
d 
10
 m
g 
zo
pi
cl
on
e 
im
pa
ir
ed
 D
S
ST
 
9 
h 
af
te
r 
in
ta
ke
. 
10
 m
g 
al
so
 
im
pa
ir
ed
 
sy
m
bo
l c
op
y 
te
st
 9
 h
 a
ft
er
 
in
ta
ke
. 
[1
17
]
N
ic
ho
ls
on
 e
t 
al
 1
98
7 
D
ou
bl
e 
bl
in
d 
cr
os
so
ve
r 
N
=
6 
H
ea
lth
y 
ƃ
vo
lu
nt
ee
rs
 
45
-5
2 
ye
ar
s 
 
D
S
ST
, 
C
om
pl
ex
 R
T
, 
S
ym
bo
l 
co
py
in
g 
Si
ng
le
 d
os
e.
 
B
ed
ti
m
e 
in
ta
ke
. T
es
ts
 
pe
rf
or
m
ed
 9
 h
 
af
te
r 
in
ta
ke
 
5,
 7
.5
 a
nd
 1
0 
m
g 
zo
pi
cl
on
e,
 
30
 m
g 
fl
ur
az
ep
am
, 
pl
ac
eb
o 
Pl
ac
eb
o
N
o 
re
si
du
al
 
im
pa
ir
m
en
t 9
 h
 
af
te
r 
in
ta
ke
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